In vivo and in vitro remodeling of a small intestinal submucosa extracellular matrix cardiac patch in an ovine model and splashing bioreactor by Scully, Brandi Braud
RICE UNIVERSITY 
In Vwo and In Vitro Remodeling of a Small Intestinal Submucosa Extracellular 
Matrix Cardiac Patch in an Ovine Model and Splashing Bioreactor 
Brandi Braud Scully 
A THESIS SUBMIITED 
IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE 
Master of Science 
/CiftM_v ~OMMITIEE 
K. Jane Grande-Allen, Ph.D. 
Associate Professor, Department of Bioengineering 
Adjunct Associate Professor, Department of Surgery 
Rice University and Baylor College of Medicine 
Committee Chair 
aniel Harrington, Ph.D. 
Faculty Fellow, Department of iochemistry and Cell Biology c ?University 
Charles D. Fraser, Jr., M.D. 
Professor, Departments of Surgery and Pediatrics 
Adjunct Professor, Bioengineering 
Baylor College of Medicine and Rice University 
Donovan Chair and Chief of Congenital Heart Surgery 
Surgeon-In-Chief, Texas Children's Hospital 
HOUSTON, TEXAS, MAY 2012 
ABSTRACT 
In Vivo and In Vitro Remodeling of a Small Intestinal Submucosa Extracellular Matrix 
Cardiac Patch in an Ovine Model and Splashing Bioreactor 
by 
Brandi Braud Scully 
Previous studies have demonstrated that surgical patches comprised of small 
intestinal submucosa (SIS)-derived extracellular matrix (ECM) have biological 
remodeling potential in various tissues. In this series of experiments, the remodeling 
potential of a commercially available cardiac SIS-ECM patch was examined in both in 
vivo and in vitro models. 
This thesis begins by introducing the clinical need for a tissue-engineered 
cardiovascular scaffold that can grow with the patient and avoid the morbidity associated 
with currently available synthetic and biological materials. Such a patch would transform 
the surgical repair of congenital heart disease, in particular of patients with tetralogy of 
Fallot and in the repair of mitral regurgitation. 
The in vivo study investigated histological, mechanical, and bioelectrical 
properties of an SIS-ECM patch implanted in the ovine right-ventricular outflow tract 
(RVOT), and the histological and mechanical properties of the same patch implanted in 
the descending aorta and main pulmonary artery of a juvenile ovine. We found the 
juvenile ovine model to be a suitable model for evaluation of SIS-ECM patch 
remodeling, as seen by in vivo echocardiography, electrical mapping, and ex vivo optical 
mapping for the RVOT patch and mechanical testing, histology and 
immunohistochemistry for patches placed in all three positions. 
The in vitro study looked at an SIS-ECM patch pretreated with pepsin, seeded 
with mitral valve interstitial cells (MVICs), and exposed to mechanical stimulation in a 
splashing bioreactor for one week. Greater cell integration and proliferation and greater 
tissue cohesion was seen in the pepsin-treated SIS-ECM, while groups without 
mechanical stimulation demonstrated a stiffening effect for the bioreactor. 
In sheep, the SIS-ECM patch appears capable of remodeling to resemble native, 
functional ventricular tissue, but further validation of this patch material is required. 
Bioreactors can play an important role in validation of this promising scaffold material. 
Tissue-engineered scaffolds are unique in their complete ontological 
metamorphosis (from scaffold material to part of the patient's own tissue) and pose 
distinctive ethical challenges that must be responsibly managed. Contract studies, such 
as the research presented in chapters 3-5, that are funded by the medical device industry 
require close scrutiny and precautions to avoid conflicts of interest. 
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Chapter 1: Introduction, Study Design, and Specific Aims 
1.1 Introduction 
Congenital cardiovascular defects remain the leading cause of death from 
congenital malformations.1 To repair these defec~ congenital heart surgeons use patch 
materials in a plethora of surgeries, including repair of interventricular defects, interatrial 
defects, reconstruction of the ventricular outflow tracts, repair of heart valves, and repair 
of the aorta. Currently, no ideal patch material exists that can be used in this population. 
The materials available for use, including polyethylene terephthalate (PET; Dacron®), 
expanded polytetrafluoroethylene (ePTFE; GORE-TEX®) and membrane materials such 
as bovine pericardium, are associated with significant morbidity. These materials can 
produce significant inflammatory response leading to calcification, can become infected 
or thrombogenic, and cannot grow with the patient, often necessitating reoperation later 
in life.2•3 When used in the repair of the mitral valve, these materials can lead to such 
complications as recurrent mitral dysfunction and thromboembolic events.4 There 
remains a great clinical need for a more optimal biomaterial to use in cardiovascular 
applications. 
Tissue engineering has been used to develop autologous vascular grafts with the 
potential for repair, remodeling, and growth. Other engineered tissues, such as heart 
valves, are being developed by seeding appropriate cell types within a suitable scaffold, 
followed by a period of incubation during which the cells remodel the scaffold and 
secrete extracellular matrix to form new tissue.5 The goal of all tissue-engineered 
materials is to have as many of the ideal features ofthe tissue they replace as possible. 
These features include (i) maintaining normal structure and biological function over a 
patient's lifetime, (ii) not causing an immunologic response, (iii) being antithrombotic, 
(iv) having the potential for growth and self-repair, (v) ease of implantation, and (vi) 
being available in an unlimited supply. 5 
Numerous scaffolds have been developed for the creation of cardiac grafts. Many 
of the designs have been biodegradable polymeric scaffolds, or grafts in which cells are 
seeded within a scaffold that degrades slowly, transferring function to the subsequent 
extracellular matrix produced by these cells. Smooth muscle cell-seeded biodegradable 
materials have been used in several applications, including repair of the right ventricular 
outflow tract. 6 
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Another approach to the problem of tissue-engineered biomaterials is the 
application of decellularized scaffolds. In the past decade, decellularized extracellular 
matrix scaffolds have become increasingly available, originating from a variety of tissue 
and animal sources.7- 13 The advantages of decellularized scaffolds as opposed to 
biodegradable ones are that they already contain the requisite strength and contain 
extracellular matrix in the correct microstructural arrangement.12•13 In addition, by 
removing the cells, it is believed that most antigenic elements are eliminated, avoiding an 
immunological response in the recipient. Collagen is the primary matrix element in these 
scaffolds, and is considered minimally antigenic.19 
Once implanted, these scaffolds can be populated by cells coming from two 
places: adjacent tissue or from the blood. Cells coming from the blood, or circulating 
progenitor cells, respond to the scaffold environment by excreting extracellular matrix (as 
would other cell types) and by changing their phenotype.11 
Small intestinal submucosa (SIS) has proven to be an especially promising 
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decellularized scaffold. It has been shown to support vascularization, tissue development, 
and restoration of regional mechanical functionality in numerous tissues in both animals 
and humans. SIS-ECM is currently being used in patients for musculo-tendinous 
replacement, bladder reconstruction, dura mater replacement, and body wall repair. 7- 10 
While many of the mechanisms responsible for remodeling of SIS-ECM scaffolds 
remain to be elucidated, several processes have emerged that appear essential for the 
remodeling process. Degradation by matrix-degrading enzymes, the phenotype of 
macrophages homing to the scaffold following implantation, the presence or absence of 
chemical cross-linking of the scaffold, and the subsequent release of growth factors and 
other cytokines have all been shown to play important roles. 20-25 These growth factors, in 
tum, promote remodeling processes including angiogenesis, cell migration and cell 
proliferation. 21'23•25 
There has been growing interest in the use of SIS-ECM to replace, repair, or 
reconstruct cardiac tissue. SIS-ECM has been used in several cardiac applications with 
promising results, but remains in the initial phase of testing. When used in the ventricle, it 
has been shown to be repopulated with myocytes in an adult pig model.20 In vessels, it 
has been shown to confer mechanical benefit in the canine model compared to Dacron?6 
In addition, SIS-ECM has been used in valve repair, specifically of the mitral valve, 
repair ofwhich with non-remodeling materials (such as Dacron or GORE-TEX) can lead 
to such complications as recurrent mitral dysfunction and thromboembolic events.4 
Small intestinal submucosa patches offer great promise and new solutions for tissue 
engineering to meet pediatric needs, and have the potential to transform the care of this 
population. The clinical applications of an SIS-ECM patch material that remodels into 
native heart tissue are virtually endless. Documenting the ability of SIS-ECM to remodel 
to cardiac tissue would validate and establish a novel graft material with significant 
implications for a patient population in critical need. The detailed analysis of 
extracellular matrix components within remodeling cardiac/cardiovascular tissues 
repaired with a cardiac patch, as presented here, offers significant insight into this 
remodeling process as well as into the suitability of the juvenile ovine model for these 
studies, and brings us one step closer to accomplishing the ultimate goal of tissue 
engineering of cardiac patches: the ability to replace damaged or absent myocardium, 
heart valves, and blood vessels with functional tissue. 
1.2 Study Design 
4 
To evaluate whether these SIS-ECM patches remodel to resemble native heart and 
vascular tissues, this body of work proposes to characterize the SIS-ECM patches by a 
number of mechanisms. To thoroughly characterize SIS-ECM remodeling potential, both 
in vivo studies, which are the most physiologically accurate but expensive and subject to 
experimental variability, and in vitro studies, which mimic in vivo conditions, are less 
expensive and more easily reproducible, are needed. Therefore we investigated the 
remodeling potential of an SIS-ECM patch both in an animal model and a splashing 
bioreactor designed by Barzilla et al.n With these experiments, we hope to gain a more 
complete understanding of this scaffold's remodeling processes. 
An in vivo study was conducted in which we implanted the SIS-ECM patches atop 
surgically created defects in the descending aorta, main pulmonary artery, and RVOT of 
a juvenile ovine model for either five or eight months. Functional tests of the patch 
placed in the right ventricular outflow tract position were then performed to assess 
mechanical function; for all three positions, mechanical testing was performed to evaluate 
elasticity and extensibility, histological stains were used to characterize the structure and 
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neovascularization of the tissue and potential for calcification, and 
immunohistochemistry was used to determine the phenotype of the cells and ECM within 
the explanted repaired tissue/patch and the presence of enzymes involved in extracellular 
matrix synthesis and turnover. 
Our goals for this in vivo study were to assess the suitability of the juvenile ovine 
model for evaluation of the histologic, mechanical, and electrical properties of a 
commercially available ECM patch following implantation in the aortic, pulmonary 
artery, and right ventricular outflow tract positions. In order to do this, we investigated 
whether the ECM patch, after 5-8 months of implantation, acts similarly to native heart 
and vascular tissue in (i) conduction of an electrical impulse, (ii) microstructure of the 
extracellular matrix, (iii) neovascularization, (iv) calcification, and (v) cell phenotype and 
proliferation. 
In addition, an in vitro study was designed to replicate the remodeling of scaffold 
materials when used to repair the mitral valve. This study aimed to evaluate the effect of 
pepsin degradation on the remodeling of SIS-ECM patches that have been seeded with 
porcine mitral valvular interstitial cells (MVICs) and subjected to mechanical stimulation 
in vitro. 
Our goals for this in vitro study were to investigate the effect of pre-treatment with 
matrix-degrading enzymes, cell-seeding with MVICs --which are key regulators of valve 
structure and function -- and bioreactor mechanical stimulation on SIS-ECM remodeling 
in vitro, through characterization of (i) mechanical properties, (ii) cell phenotype and 
proliferation, and (iii) microstructure of the extracellular matrix. 
1.3 Specific Aims 
1.3.1 Specific Aim 1: Assess the suitability of the juvenile ovine model in evaluating 
the remodeling of an SIS-ECM patch implanted in the right ventricular outflow 
tract. 
Hypothesis: SIS-ECM patches will have the ability to remodel when placed in the 
right ventricular outflow tract of a juvenile ovine model. 
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Approach: Remodeling was characterized using in vivo contact echocardiography 
and electrical mapping, optical mapping on explanted, Langendorff-perfused hearts, 
and mechanical testing, histology, and immunohistochemistry on explanted tissue. 
Significance: SIS-ECM patches were shown to remodel in the RVOT position. With 
confinnation of these promising results through further evaluation including larger 
sample sizes and control arms, the potential clinical applications are abundant and 
would have the potential to transform care of patients needing patched repair of 
their RVOT such as patients with tetralogy ofFallot. 
1.3.2 Specific Aim 2: Assess the suitability of the juvenile ovine model in evaluating 
the remodeling of an SIS-ECM patch implanted in the descending aorta and main 
pulmonary artery. 
Hypothesis: SIS-ECM patches will have the ability to remodel when placed in the 
pulmonary artery and aortic positions of a juvenile ovine model. 
Approach: Remodeling was characterized using mechanical testing, histology, and 
immunohistochemistry on explanted tissue. 
Significance: SIS-ECM patches were shown to remodel in the aorta and pulmonary 
artery positions. As in Aim 1, these promising results should inspire further pre-
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clinical evaluation, because the potential clinical applications are abundant and 
would have the potential to transform care of patients needing patched repair of the 
aorta or pulmonary artery. 
1.3.3 Specific Aim 3: Optimize and evaluate the remodeling of an SIS-ECM patch 
undergoing enzyme degradation, seeding with MVICs, and culture in a mechanical 
stimulation bioreactor. 
Hypothesis: SIS-ECM patches will demonstrate superior remodeling when they are 
pre-treated with matrix-degrading enzymes, seeded with MVICs, and subjected to 
mechanical stimulation from a splashing bioreactor. 
Approach: Remodeling will be characterized using mechanical testing, histology, 
and immunohistochemistry on SIS-ECM patches with and without mechanical 
stimulation. 
Significance: Establishing an in vitro model that allows further investigation into 
the importance of enzymatic pretreatment and the crucial role of MVICs in valve 
remodeling will aid in the translation of this technology to the clinical setting. 
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Chapter 2: Background 
2.1 Congenital Heart Disease and Tissue Engineering Applications 
Congenital heart defects occur in close to 1% of live births in the United States, and 
can impede adequate circulation and threaten the development of multiple organ systems, 
including the heart and lungs. 23 The goals of surgical repair of congenital heart disease 
include establishing anatomic continuity and achieving a physiologic circulation. 3 This 
often requires that congenital heart surgeons use valves, conduits, and a variety of patch 
materials, which are associated with significant morbidity and mortality secondary to 
thrombosis, infection, their inability to grow with the patient, and arrhythmias, and can 
lead to multiple reoperations. 2'3 
Surgical repair of congenital heart disease began in 1939, when Dr. Robert Gross 
published a report chronicalling the first successful patent ductus ligation.29 In 1944, at 
Johns Hopkins Hospital, Dr. Alfred Blalock performed the first surgical palliation of 
tetralogy ofFallot (TOF), a congenital heart syndrome consisting of four different 
anomalies: right ventricular hypertrophy, pulmonary stenosis, an overriding aorta, and a 
ventricular septal defect.19 Without surgery, 35% ofTOF patients die before they reach 
one year of age, 50% by the age of three, and very few survive into adulthood. 
In their landmark paper chronicling their first three operations on cyanotic babies, 
Helen Taussig and Blalock set forth their argument for surgery: "The operation here 
reported and the studies leading thereto were undertaken with the conviction that even 
though the structure of the heart was grossly abnormal, in many instances it might be 
possible to alter the course of the circulation in such a manner as to lessen the cyanosis 
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and the resultant disability".19 Nine years later, Lillehei and his team first completed an 
intracardiac repair of a tetralogy ofF allot patient, and physicians could begin to 
surgically address the malformations associated with the syndrome. 30--32 These early 
operations are considered the dawn ofboth congenital and adult cardiothoracic surgery.33 
This is particularly relevant to the current study, as TOF patients often require RVOT 
patch placement following their primary repair. Thus, TOF patients continue to be at the 
forefront of advancements in the field of congenital heart surgery, as researchers work to 
create tissue-engineered patches capable of meeting this patient population's needs. 
The following decades saw advances in surgical technique, and between 1970 to 
1990, the introduction of prostaglandins, advances in infant surgery, and the rise of 
echocardiography greatly improved outcomes for patients with congenital heart disease.31 
These advances have led to the current 30-day mortality rate of less than three percent for 
tetralogy ofFallot patients undergoing surgical repair.34 The mortality rate has similarly 
dropped for all patients with cardiac defects requiring repair, and over 1 million adults 
are now living with congenital heart disease. 35 
As the field has advanced, the use of patch material has allowed repair of more and 
more complicated malformations, enabling surgeons to establish anatomic continuity and 
physiologic restoration.3 For example, in patients with tetralogy ofFallot, a prosthetic 
conduit is often required to restore blood flow from the right side of the heart to the 
pulmonary system. In this study, we investigated the remodeling of a tissue-engineered 
cardiac patch implanted in the right ventricular outflow tract, a tissue-engineered 
application particularly relevant to tetralogy ofFallot patients, many of whom have 
undergone a transventricular patch repair and often return for pulmonary valve 
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replacement requiring right ventricular outflow tract patch placement. 
2.2 Tissue Engineering of Cardiovascular Patches 
No ideal patch material exists for use in the repair of congenital heart defects. The 
materials available for use include polyethylene terephthalate (PET; Dacron®), expanded 
polytetrafluoroethylene ( ePTFE; GORE-TEX®) and membrane materials such as bovine 
pericardium. Dacron has been shown to induce a healing response leading to formation 
of scar tissue and contracture of the implant, thickening and increased stiffness. 36•37 
Bovine pericardium has been shown to be associated with graft calcification and 
contraction.38•39 All synthetic materials lack the ability to grow, remodel or regenerate. 
They are not chemotactic and cannot be functionally degraded, and thus cannot grow 
with the patient, often necessitating reoperation later in life. 3•4 Even native materials such 
as autologous pericardium, though they do not trigger an immune response, become 
fibrotic and retracted and can become aneurysmal and arrhythmic.38•40 In TOF, this can 
lead to decreased right ventricular output, resulting in right ventricular failure for these 
patients, who often require multiple reoperations. A clinical need exists for a 
bioresorbable biomaterial for use in cardiovascular repair applications. 
One approach to this problem is the use of cell-seeded biodegradable scaffolds. 
These scaffolds require that cells be harvested and seeded on the scaffolds prior to 
implantation. Cardiac patches have been engineered for repair of congenital heart defects 
by seeding autologous human umbilical cord-derived fibroblasts and endothelial 
progenitor cells on polyglycolic acid (PGA) scaffolds.41 Vascular patches have been 
constructed using autologous cells harvested from peripheral veins seeded onto polymer 
scaffolds.42 Vascular patches have also been constructed by seeding bone marrow-' 
derived cells onto decellularized scaffolds made from dog inferior vena cava.43 
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Another approach to this problem is the use of decellularized extracellular matrix 
scaffolds.44 In contrast to synthetic biodegradable meshes, decellularized scaffolds 
contain extracellular matrix that can remodel, signal surrounding cells, and immediately 
serve as a load-bearing scaffold.12•13 Extracellular matrix derived from porcine small-
intestinal submucosa (SIS-ECM) in particular has been shown to be chemotactic (Reing 
et al. 200945) and once implanted can become populated with progenitor cells from 
adjacent tissues as well as marrow-derived stem cells from the circulation.46-48 Bone 
marrow cells can differentiate into smooth muscle cells and endothelial cells, and in vivo 
have been shown to differentiate into cell types that contribute to antiogenesis and 
vasculogensis.11 Following migration and attachment, these cells can undergo 
proliferation, differentiation, and phenotypic maturation, remodeling the implanted 
scaffold into functional tissue in the process. 49'5° Furthermore, because all of the porcine 
cells are rem.oved from the scaffold during processing, and because collagen is the 
primary matrix element remaining, these materials are considered minimally antigenic.5 
2.3 Small Intestinal Submucosa Scaffolds 
In both animals and humans, decellularized, SIS-derived scaffolds have been 
shown to support vascularization, tissue development, and restoration of regional 
mechanical functionality in numerous tissues. These materials are currently being used in 
humans for musculotendinous replacement, bladder reconstruction, dura mater 
replacement, and body wall repair.7- 10 
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A commercial SIS-ECM product (CorMatrix) has also been cleared in the US and 
Europe for human cardiac tissue repair and pericardia! closure as a patch only with no 
remodeling indication in the US (Fig. 2.1).51- 53 In preclinical models this material has 
been shown to be repopulated with myocytes20 and to confer regional mechanical benefit 
in canine and bovine cardiac-repair models, which has led to its CE approval for cardiac 
tissue repair in Europe.26 54 
Figure 2.1 The CorMatrix patch prior to implantation. The patch is 4-ply and once 
rehydrated extremely difficult to tear. Photo taken by the author. 
CorMatrix patches are decellularized using detergents and then freeze-dried with core 
components including proteoglycans and growth factors within the matrix. There appears 
to be little or no calcification following implantation, making the patch especially useful 
in pediatric populations. There is also evidence that the CorMatrix patch is replaced by 
neighboring myocardial or vascular tissue. Therefore, it has the possibility of both 
restoring tissue functionality and growing along with the child, eliminating the need for 
multiple repeat surgeries. 
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2.4 Mitral Valve Disease and Surgical Considerations 
Degenerative mitral valve disease is the most common cause of mitral regurgitation 
in developed countries. 55 Mitral regurgitation is precipitated by leaflet prolapse, which 
can be caused by chordae elongation or rupture, and is associated with annular dilation. 
These anatomic changes can lead to clinical symptoms, including atrial fibrillation, 
pulmonary hypertension, and left ventricular dysfunction. 55 
The mitral valve often must be surgically repaired to address diseases such as 
myxomatous degeneration, the most common cause of mitral regurgitation in older 
patients (incidence of2.4-5%).56•57 Clinicians prefer repair of the mitral valve over 
replacement with a bioprosthetic or mechanical valve, due to repair offering superior 
long-term results and the ability to avoid lifelong anticoagulation treatment. 58 Mitral 
valve replacement can lead to an increased risk of endocarditis, thrombosis, infection, 
calcification, and bleeding from chronic anticoagulation. 3 In addition, children have a 
greater risk of calcification of implanted valves and an accelerated rate of 
degeneration. 28•59•60 Surgical repair is considered superior to replacement of the mitral 
valve, with lower operative mortality, improved late survival, preservation of left 
ventricular function, decreased risk of endocarditis, and avoidance of antiocoagulant-
related complications such as hemorrhage.61 •62 
An understanding of mitral valve anatomy and function is necessary for successful 
repair of the mitral valve. 62 The mitral valve is one of four heart valves, and one of two 
atrioventricular valves (Fig.2.2). 
Fig. 2.2: (Left) Bailey' s analogy of a mitral valve woman's girdle with garters (unpublished figure 
prepared for Bailey' s manuscript of 1 988). http://ats.ctsneqoumals.org/cgi/ 
content/full/65/6/1 809/FIG 1 (Right) Mitral valve anatomy, showing the mitral valve structure, 
including the annulus, leaflets, cho dae tendinae and papillary muscles Kunzelman S · in D 
Cochran RP. Auid-structure interaction models of the mitral valve: function in normal and 
pathological states. Phil Trans R Soc B 2007;362:1393-1406. 
Functional components of the mitral valve include the left atrial wall, the annulus, the 
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anterior and posterior leaflets, chordae tendinae, the papillary muscles and part of the left 
ventricular myocardium. 62 Abnormal anatomy or dysfunction of any of these 
components can lead to mitral valve dysfunction. 63 Mitral valve prolapse caused by 
degenerative disease can range from a simple chordal rupture that involves prolapse of an 
isolated segment, most commonly in the posterior leaflet, to multi-segment prolapse 
involving both leaflets in a valve with a large annular size along with significant excess 
tissue. 58 Surgeons use a variety of surgical techniques to repair the mitral valve, which 
continue to evolve as new materials become available. 
Scaffold material is often used in mitral valve repair, including polyethylene 
terephthalate (PET; Dacron®), expanded polytetrafluoroethylene (ePTFE; GORE-
TEX®) and membrane materials such as bovine pericardium (Figure 2.3). 
15 
Fig. 2.3: Mitral valve repair in which synthetic materials are currently used: GORE-TEX loop technique 
and ring annuloplasty. A) Fibroelastic deficiency with anterior lateral scallop prolapse. B) GORE-TEX 
loops are constructed, and the apparatus is attached to the fibrous tip of the papillary muscle. C) Individual 
loops are attached to the prolapsing segment margin. D) Completed repair after ring annuloplasty. Adams 
DH, Rosenhek R, and Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart 
J 201 0;31 :1958-67. 
However, when used in the repair of the mitral valve, these materials can lead to such 
complications as recurrent mitral dysfunction and thromboembolic events. 4 In contrast, a 
tissue-engineered scaffold with remodeling ability would have the potential to improve 
the outcomes of mitral valve repair and replacement when patches are used. 
In the past decade, decellularized extracellular matrix scaffolds have become 
increasingly available, originating from a variety of tissue and animal sources.7- 10 These 
scaffolds contain extracellular matrix that can remodel, be invaded by surrounding 
progenitor cells in neighboring tissue and marrow-derived stem cells from the circulation, 
and can bear load immediately upon implantation. 14' 18 One such scaffold, SIS-ECM has 
been shown to remodel in tissues throughout the body, including the cardiovascular 
system, in myocardium, blood vessels, and in venous valves.2664 However, its ability to 
remodel is not fully understood, and its experience in mitral valve repair operations is 
primarily anecdotal. Further investigation of the remodeling of SIS-ECM when used in 
mitral valve applications is needed. 
2.5 Bioreactors 
Although animal models are often used to study tissue-engineered scaffolds (as 
we have done in our investigation of the remodeling of an SIS-derived cardiac patch in 
sheep), these models are expensive and require a large number of animals to assess 
multiple time points. 27 Bioreactor systems, in which investigators create an in vitro 
experimental model, can be used to apply mechanical stimuli to scaffolds seeded with 
cells from various tissues, as mechanical stimulation has been found to be crucial for 
maintaining tissue strength and architecture.65•66 
Interest in replicating aspects of the in vivo conditions experienced by the mitral 
valve led to the creation of several in vitro systems that allow dynamic culture of the 
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valve components. These systems apply mechanical forces to the valve components and 
have demonstrated the ability to maintain the same density and distribution of 
extracellular matrix and cells as native mitral valve tissue, thus allowing investigation 
into the effects of drugs and chemicals that have been shown to cause heart valve 
lesions.67- 70 These systems allow valve cells, including the two major mitral valve cell 
types, valvular endothelial cells (VECs) and valvular interstitial cells (VI Cs ), to respond 
to mechanical and chemical stimuli by modulating their production and degradation of 
proteins, collagen, glycosaminoglycans (GAGs), and DNA.(Barzilla et al. 2010; Weston 
& A P Yoganathan 2001;72) Mitral VICS, which have characteristics ofboth fibroblasts 
and smooth muscle cells, are key regulators of valve structure and function in both 
d. sed al 73--75 normal and 1sea v ves. 
A wide variety ofbioreactor designs for heart valve culture have been developed. 
· ha · I ded fl I 7611 I" 1t1s d I" fl 79,so These designs ve me u ow oops, · eye IC pressure, · an eye IC exure, 
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and have tended to be applied to semilunar (aortic and pulmonary) valve applications. In 
the Grande-Allen lab, two bioreactors have been developed for the study of the mitral 
valve. One, used for intact mitral valves, is a flow loop organ culture system that can 
recreate physiologic pressure waveforms up to 150 mmHg and induce pulsatile flow. 70 
The other, a splashing bioreactor that applies mechanical stimulation to mitral valve 
leaflet segments, has been shown to maintain tissue integrity when compared to static 
culture.27 
2.6 Matrix Degradation and Its Role in Sea:IJold Remodeling 
While many of the mechanisms responsible for remodeling of SIS-ECM scaffolds 
remain to be elucidated, degradation by matrix-degrading enzymes appears essential for 
the remodeling process. For instance, the phenotype of the macrophages that home to the 
area of scaffold implantation has been shown to greatly influence remodeling outcomes. 24 
Chemically cross-linked scaffolds attract pro-inflammatory, cytotoxic macrophage 
phenotypes (Ml), whereas non cross-linked scaffolds attract anti-inflammatory 
macrophage phenotypes (M2) that promote tissue repair and remodeling?4 The ability of 
the host tissue response to degrade the extracellular matrix scaffold, which is impaired 
with cross-linked scaffolds, has been shown to be an essential factor in remodeling 
outcomes.22•79 In addition, macrophage (M2) degradation generates a short protein 
fragment that acts as a powerful chemoattractant to stem and progenitor cells. 24 Any 
accurate in vitro system of scaffold remodeling must therefore include matrix 
degradation. 
Recent attempts to replicate matrix degradation in vitro have shed new light into 
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how degradation products can affect matrix remodeling. Degradation of the extracellular 
matrix following implantation has been shown to release component growth factors, 
which then promote remodeling processes including angiogenesis, cell migration and cell 
proliferation.21 •23•25 In vitro studies have mimicked this degradation by enzymatically 
degrading the extracellular matrix prior to cell seeding; this enzymatic degradation 
increases migration and proliferation of cells.21•25•81 Pepsin digestion should help 
progenitor like VICs migrate into SIS-ECM. Reing et al showed that decellularized 
ECM, following degradation by mild enzyme treatment, was active in promoting the 
migration and proliferation of progenitor cells in vitro.25 
Considering the importance of extracellular matrix degradation and the crucial 
role of mitral VICs in valve pathogenesis, an in vitro experiment was designed to 
replicate mitral valve scaffold material remodeling. This study aims to evaluate the effect 
of pepsin degradation on the remodeling ofSIS-ECM patches that have been seeded with 
porcine mitral VICs and subjected to mechanical stimulation in vitro, as stated in Aim 3. 
Establishing an in vitro model that allows further investigation into the importance of 
enzymatic pretreatment and the crucial role ofMVICs in valve remodeling will aid in the 
translation of this technology to the clinical setting. 
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Chapter 3: Research Designs and Methods: In Vivo Study1 
3.1 Animal study design 
3.1.1 Ethical statement and considerations 
Before delving into the animal study design, it must first be disclosed that much of 
this work was industry funded, by CorMatrix, Inc., who also supplied the extracellular 
matrix patches used in these studies. 
In addition, the funding provided allowed for a small sample size of four sheep. 
Therefore, this study, rather than being a definitive look at the full remodeling potential 
of these extracellular matrix patches, is an assessment of the juvenile ovine model's 
suitability for evaluation SIS-ECM remodeling and a development of strategies for this 
assessment. 
Furthermore, due to the fact that there were no patch controls, there was no way of 
blinding for this data analysis. Therefore, to guard against subjective bias, the 
histological and immunohistochemical analysis was performed in an automated manner, 
which we will discuss further. 
Finally, it is important to note that we had complete treedom of scientific inquiry 
for these studies. CorMatrix, Inc. did not participate in the study design, they did not 
have access to the data as it was being collected nor did they, by contract, influence 
which data to publish or review any manuscripts prepared for publication. 
1 The majority of this and the following chapter are being prepared for submission to The 
Journal of Thoracic and Cardiovascular Surgery and will be published as Scully BB, Fan 
C, Grigoryan B, Jacot JG, Vick GW, Kim J, Fraser CD, Grande-Allen KJ, and Morales 
DLS. In Vivo Remodeling of an Extracellular Matrix Patch into Functional Myocardium 
in an Ovine Model. 
20 
3.1.2 Choosing an animal model 
The juvenile ovine model has been consistently recommended as the most relevant 
to human cardiovascular performance. Prior studies have demonstrated the efficacy of the 
ovine model for implantation of extracellular matrix scaffolds. 82 The ovine model has 
shown similar histopathologic and histochemical changes in allograft heart valves as 
compared to human allograft valves. 83 In addition, patches implanted in juvenile ovine 
have been shown to calcifY quickly, making them an ideal model to study implanted 
scaffold calcification. 82 In the present study, a juvenile ovine model was used to evaluate 
the histologic, mechanical, and electrical properties of a commercially available 
extracellular matrix patch following implantation in the RVOT, descending aorta, and 
main pulmonary artery. 
3.1.3 Animal protocol 
Juvenile male weathers (37-49 kg, less than one year old) were obtained from a 
vendor and held for a minimum of 14 days of quarantine and acclimation prior to 
enrollment in the study. Animals were given routine care and feeding during the 
preoperative period. 
Prior to surgery, animals were placed in a stanchion for acclimation and shaved in 
the left thoracotomy region. 24 hour monitoring was done while the animal was in the 
stanchion. An IV catheter was placed in the animal's jugular vein for fluid hydration. 
Food was withheld 18-24 hours prior to surgery and water administered ad libitum. On 
the morning of surgery a blood sample and an activated clotting time were drawn. 
Animals were anesthetized with atropine (0.04-0.8 mg/kg IV), xylazine (0.01-0.33 mg/kg 
IV), and ketamine (5-20 mg/kg IV) prior to surgery. Cephazolin (15-30 mg/kg IV) 
prophylaxis was given. In addition, animals were given Buprenorphine (0.01 mg/kg 
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IV liM q 6 hrs), Banamine (1 mg/kg IV liM q 8-12 hrs), or other appropriate analgesic at 
the discretion of the attending veterinarian. 
Four juvenile ovine were taken to the operating room in the Michael E. DeBakey 
animal laboratory at Baylor College of Medicine (BCM). Following transport into the 
operating room, animals were placed in the right lateral recumbency position. A rumen 
tube was placed and a rectal temperature monitor was placed. A left thoracotomy was 
performed and the pericardium was incised from the left ventricle apex to the pulmonary 
artery. The pulmonary artery, right ventricle, and descending aortic patches were 
anastomosed using a side clamp and 2 em-long, full-thickness defects created using a 
scalpel. A 2 x 2 em decellularized SIS-ECM patch (CorMatrix ECM®, CorMatrix 
Cardiovascular Inc, Atlanta, GA) was sewn to the defect using a running 4-0 
polydioxanone suture using a running suture technique. While the defect created was a 
full thickness defect, it was a slit defect (in which the cut edges could potentially re-
oppose and heal) rather than a critical size defect (which would be incapable of healing 
on its own). The patch we sewed in was aneurysmal rather than pulled taut so that the cut 
edges of the defect would not be re-opposed during the initial surgical repair procedure. 
The sutures employed were PDS (polydioxanone), a mono-filament synthetic absorbable 
suture. These sutures cause minimal tissue reaction and degrade completely by 180 
days84• Native pericardium was not reanastomosed, as it is not routinely anastomosed in 
children undergoing congenital heart surgery. A chest tube to drain air and fluid was 
placed prior to closure of the thoracotomy. 
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A 19G Perineural catheter was placed along the incision line prior to closure for 
postoperative infusion ofBupivicaine, which was administered for three days. All 
incisions were then closed using Vicryl in the subcutaneous layers and a skin stapler on 
the outside skin. All skin sutures or wound clips were removed within 10 days. 
Extubation was done when the animal was able to swallow and maintain a satisfactory 
saturated P02 while breathing room air. A fentanyl patch was placed on the animal at the 
end of the surgery at a dose of 1 meg/kg. Banamine and bupivicaine were administered 
for at least three days. 
Following surgery, the sheep were recovered in ICU 414SA within the 4th floor 
experimental surgery-satellite area and monitored continuously. Once the sheep were 
standing, they were fed alfalfa pellets and straw and given water ad libitum. Vital signs 
and urine output were monitored every hour until the sheep was stable enough to remove 
the chest tube (typically from 6 to 24 hours) and return to the animal facility. 
Two sheep were randomly selected for reoperation and euthanasia after 5 months, 
and the other 2 at 8 months. These time points were chosen based on prior studies 
showing that decellularized scaffolds implanted in the aorta and pulmonary artery of an 
ovine model calcify after 20 weeks32 and that decellularized ECM completely degrades 
within 3 months. 85 
The ovine was returned to the operating room, where a redo left thoracotomy was 
undertaken and in vivo echocardiography and electrical mapping were performed (as 
detailed below). Following this, cardioplegia was infused and the hearts explanted and 
placed on ice for transport. The sheep were humanely euthanized in a manner consistent 
with the American Veterinary Medicine Association Guidelines on Euthanasia 2007 and 
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their hearts explanted.86 This protocol was approved by the IACUC at BCM. 
3.2 In Vivo Echocardiography 
Following repeat thoracotomy under anesthesia with glycopyrrolate (0.01-0.025 
mg/kg SQ), epicardial echocardiography was performed on each sheep using a Vivid Q 
portable echocardiography machine (General Electric, Milwaukee, WI). The RVOT and 
surrounding structures were visualized and M mode and 2-dimensional 
echocardiographic evaluation was performed, in collaboration with a pediatric 
cardiologist specializing in echocardiography. 
3.3 In Vivo Contact Electrical Mapping 
Contact electrical mapping was then performed using a Polaris DX 5575 6-lead 
catheter (Boston Scientific, San Jose, CA). The electrical activity of the patch and the 
surrounding right ventricle were assessed by measuring the electrical potential between 
the leads inside the patch using Vetronics software (BASi, West Lafayette, IN), and data 
was then transferred from analog printouts through MA TLAB software (Math Works, 
Natick, MA) to digitized data. The amplitude of the signal was then calculated by 
measuring the difference between the maximum and minimum of the measured 
waveform. 
3.4 Ex Vwo Optical Mapping 
3. 4.1 Langendorff Perfusion Setup 
A Langendorff perfusion system was created using water-jacketed Radnoti 
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glassware (Radnoti, Monrovia, CA), a Radnoti water bath maintained at 41 degrees 
Celsius connected to a heater circulating pump (Radnoti, Monrovia, CA), two peristaltic 
pumps (4-600 mL/min, VWR, Radnor, PA) and 95% (h 5% C02 bubbled in from a wall 
port. The Tyrode's Solution (made with ultra pure water, 123 mM NaCl, 4.5 mM KCl, 
1.8 mM CaCh, 0.98 mM MgCh, 20 mM NaHC03, 1.01 mM NaH2P04, and 11 mM 
dextrose, with albumin 0.04 giL added to reduce edema) was pumped into a 2L reservoir, 
where 95% (h 5% C(h was bubbled in. From there, the solution was pumped into the 
bubble trap, where it flowed to a heating coil and into the cannulated heart's aorta. After 
retrograde perfusion of the heart, the Tyrode's solution was collected in the bottom of the 
heart chamber and pumped back into the reservoir through a paper filter. 
Constant pressure was maintained at between 45-60 mm Hg and measured using a 
Pressure Display 60000 (Medtronic, Minneapolis, MN). Blood gases were drawn on the 
Tyrode's solution using an Instrumentation Laboratory Blood Gas Machine (Model GEM 
3000) and pH, pC02, p(h, Na, K, Ca, Glu, lactate, and hematocrit monitored every 30 
minutes. Pacing wires were placed and the heart was paced at 1 Hz. A defibrillator was 
used to return the cannulated heart to normal sinus rhythm in the case of ventricular 
fibrillation, beginning at 20 J and increasing to 30 J and then 50 J. 
3.4.2 Optical Mapping Study Design 
For ex vivo whole-heart electrical studies, the SIS-ECM patched hearts were 
explanted and the animals humanely euthanized. The hearts were infused with 
cardioplegia, immediately placed on ice, and then subjected within one hour to voltage-
sensitive dye mapping, in order to assess the connection to and integration of the patch 
into the heart wall. 87 Briefly, the explanted hearts were continuously perfused with 
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Tyrode's solution using the Langendorffmethod.88 On resumption ofbeating, they were 
infused with a dual-emission, voltage-sensitive, ratiometric fluorescent dye ( di-4-
ANEPPS, 1 IJM; Molecular Probes, Portland, OR). 2,3-butanedione (BDM) was added to 
delay tissue swelling. The conduction of electrical impulses in the implanted patches was 
compared to that of native heart tissue by pacing the heart at 1 Hz with a voltage of 1.5 V 
and then illuminating the heart with a light-emitting diode array at a frequency near 502 
nm. Light emissions near 540 nm and 610 nm were captured simultaneously using a 560 
nm dichroic mirror to send the emitted light into separate digital cameras (Pike P-032B; 
Allied Vision Technologies, Stadtroda, Germany) fitted with optical filters (Omega 
Optical, Brattleboro, VT) at approximately 982 frames per second. 
Images from both cameras were recorded simultaneously using Streampix 5 
Multicamera software (Norpix, Inc. Montreal, Quebec, Canada) and analyzed using 
MA TLAB. The ratio of the emission intensities was used to calculate the voltage 
potential across the cell membrane. Fast Fourier analysis of each pixel utilizing 
MA TLAB was conducted to isolate primary frequencies present. Pacing occurred at 1 
Hz; therefore, frequency at 1 Hz was isolated and visible peaks were seen on the 
epicardium of the heart. From the Fourier analysis, we calculated the phase of the 1Hz 
waveform. From the phase analysis, we converted the phase to a time-shift 
depolarization, in which the depolarization time of the right ventricular face and the 
speed and direction of the depolarization wave across the SIS-ECM patch were 
visualized. 88•89 The Optical Mapping MA TLAB Code used, developed by Chris Fan, can 
be found in Appendix 1. 
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3.5 Tissue Preparation 
Following optical mapping, the harvested tissue was dissected, reserving 2 mm-wide 
sections of patched and native tissue for mechanical testing. Additional 2 mm-wide 
sections were fixed in I 0% neutral buffered formalin and dehydrated using a series of 
graded flex and xylene (VWR., Radnor, PA). They were then embedded in paraffin and 
cut into 5-micron thick sections using a rotary microtome and affixed to glass slides for 
histological and immunohistochemical evaluation (described in sections 3.8 and 3.II). 
3.6 Mechanical Testing 
Mechanical testing was performed to compare the elastic modulus ( stiffuess) and 
extensibility of native and patched tissue. The width and thickness of each tissue section 
(I section from each patch and 2 from the surrounding myocardium of each heart) was 
measured in 3 positions and averaged. The ends of each length of tissue were affixed to 
balsa wood mounts with cyanoacrylate (Loctite 435, Henkel, Rocky Hill, en. The 
wooden mounts were clamped into an Enduratec 3200 mechanical tester (Bose 
Corporation, Eden Prairie, MN) and the sample was extended to a taut length, bearing 0 
N load. This "gauge length" of the tissue was recorded and preconditioning was 
performed using I 0 stretch-unstretch cycles of increasing stretch magnitude. The sample 
was then pulled to tension at a rate of0.4 mm/sec until reaching a final length of I 55% of 
the original length in order to ensure a greater than I 50% extension ratio. Load and 
deformation values were converted to stress and strain by dividing by the sample cross-
sectional area (width x thickness) and gauge length, respectively. The elastic modulus 
was obtained for each tissue section by calculating the slope of the linear portion of the 
stress-strain curve and its x-intercept represented the tissue extensibility. 
3. 7 Strain Mapping 
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For the aorta and pulmonary artery patches, a grid was applied to the each SIS-
ECM sample using a mesh sheet dipped in charcoal and impressed onto the tissue. A 
Pike032B CCD (FPS) camera was used to record the deformation of the tissue. Digital 
image correlation code originally written by Christopher Eberl and adapted by 
Christopher Durst was used to track the displacement of the charcoal dots in each frame 
of the video.90•91 MATLAB code was used to analyze the resulting displacement and 
generate maps that illustrate regional tissue strain; this code can be found in Appendix 2. 
3.8 Histology 
3.8.1 Histology Background 
The remodeled SIS-ECM patch was compared to two controls, the segment of the 
native heart tissue previously mentioned, and a negative control, SIS-ECM that had not 
been implanted in the ovine model. Several types of stains were performed to determine 
the extent to which vascular tissue had replaced the SIS-ECM, in the case of the SIS-
ECM patches in the pulmonary artery position and the aorta, and myocardial tissue in the 
case of the SIS patches placed in the right ventricular outflow tract. 
To evaluate the overall microstructure of extracellular matrix within the tissue as 
well as the extent of formation of new blood vessels in the SIS-ECM patch, general 
multicolor histological stains were used to demonstrate the normal layered structure of 
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the vessel (specifically, looking for the presence of intima, media, and adventitia) for 
SIS-ECM patches in the aorta and pulmonary arteries, and to quantifY the diameter of the 
cardiac fibers in the SIS-ECM patches placed in the right ventricular outflow tract. 
3. 8. 2 Movat Pentachrome 
Movat pentachrome staining allowed visualization of several extracellular matrix 
components, including collagen (yellow), elastin (black), glycosaminoglycans (blue), 
muscle and fibrin (red), and nuclei (dark purple). These stains were performed by using 
serial baths of Alcian Blue (1% w/v Alcian Blue and 0.09% v/v acetic acid in ddilliO, 
Acros Organics, Geel, BE), alkaline alcohol (1 0% ammonium hydroxide, 4.5% ddiH20, 
85.5% ethanol), Voerhoff's Hemotoxylin (5% w/v hemotoxylin in ethanol; 2% w/v 
iodine, 4% potassium iodide in ddiH20; 10% w/v ferric chloride hexahydrate in ddilliO; 
mixed 2: 1 : 1 volumetrically, respectively), ferric chloride (2% w/v in ddiH20 ), aqueous 
sodium thiosulfate (5% w/v in ddiH20), Crocein Scarlet (0.1% w/v Brilliant Crocein 
MOO and 0.5% v/v acetic acid in ddilliO; 0.1% w/v acid fuschin and 0.5% v/v acetic 
acid in ddilliO; mixed 1:1 volumetrically; Acros Organics), 0.5% acetic acid, two 
changes ofphosphotungstentic acid (5% w/v in ddiH20), pure ethanol, and Safran (6% 
w/v in ethanol, Poly Scientific, Bay Shore, NY). 
3.8.3 Masson's Trichrome 
Masson's trichrome (adapted from Kiernan's Histological and Histochemical 
Methods92) staining allowed excellent visualization of collagen fibers (blue), muscle 
fibers (red) and cell nuclei (dark purple). These stains were performed using serial baths 
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ofLillie's iron-hematoxylin (1.1% alcoholic hematoxylin: 1.0 g ofhematoxylin dissolved 
in 100 ml of 95% ethanol and an iron salts solution of 12.5 g ferric chloride and 24.5g 
ferrous sulphate in 3298 mL of distilled water and 42.0 mL of concentrated hydrochloric 
acid), 1% Biebrich scarlet (5 g Biebrich scarlet, 495 ml distilled water, 5 ml glacial acetic 
acid), PMA-PTA solution (5 g phosphomolybdic acid, 5 g phosphotungstic acid, in 200 
ml distilled water), 2.5% Fast green FCF (50 g Fast Green FCF in 195 ml water and 5.0 
ml glacial acetic acid) and acidified water (1 ml glacial acetic acid added per 200 ml 
distilled water). 
3. 8. 4 Alizarin Red 
To ensure that the SIS-ECM patch had not calcified in the pulmonary artery and 
aorta positions, sections were stained with alizarin red (alizarin red solution in distilled 
water, adjusted to pH 4.1-4.3 with 10% ammonium hydroxide) and compared to a 
calcified control (bone from a rabbit skull). 
3.9 Cardiac Fiber Diameter Quantification 
Masson's trichrome stained slides were used to quantify cardiac muscle fiber 
diameter for the RVOT patches and surrounding native tissue. Slides were scanned and 
analyzed in ImageJ (NIH, Bethesda, MD) after calibrating the scale for 3.5 microns per 
pixel. Five areas of interest were chosen and a line drawn perpendicular to several 
muscle fibers, and the line tool used to determine the length of the line in the scale 
already set. Muscle fibers were counted and the line length divided by number of fibers 
to determine the average fiber diameter. 
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3.10 Quantification of Neovascularization 
Masson's trichrome stained slides were also used to quantifY patch 
neovascularization for all three patch locations. In Adobe Photoshop (Adobe, San Jose, 
CA) the counting tool was used to manually count each blood vessel. Following this, 
ImageJ was used to select the total area of interest for both patch and native tissue and the 
area was divided by the number of vessels to determine blood vessel density in vessels 
per area. All patch area and native tissue area was analyzed for each slide. 
3.11 Immunohistochemistry 
3.11.1 immunohistochemical stains 
Several immunohistochemical stains were used to demonstrate markers for specific 
types of extracellular matrix components, including collagen, elastin, and proteoglycans, 
and markers related to the basement membrane, matrix degradation, and cell proliferation. 
To determine the phenotype ofthe cells within the SIS-ECM patch, additional 
immunohistochemistry was performed. For the SIS-ECM patches in the pulmonary artery 
and aortic positions, stains were performed for several characteristic markers of vascular 
smooth muscle cells (these cells should be located in the media), vascular endothelial 
cells (intima), and vascular fibroblasts (adventitia), as shown in Table 3.1. 
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Table 3.1 Aorta and PA Patch IHC Markers and Their Function 
L:'\, : --~-,-, : ~ . . . --. - '-
.. ' ~ I ~ !• ~ 
·- 40 "' .~ ...... 
Lysyl Oxidase Cross-linking enzyme in collagen synthesis 
Calponin hl Stabilizes the actin network in vascular 
smooth muscle cells. It can regulate actin 
contraction and hence is a marker of the 
contractile ability of mature smooth muscle 
cells. 
Smooth muscle Expressed by smooth muscle cells (an early 
alpha actin stage marker of this phenotype). 
Matrix Enzyme involved in matrix degradation. 
meta 1/oprotease 
I 
L/PG Expressed in coronary artery endothelial 
cells, has phospholipase and triglyceride 
lipase activity and binds heparin 
For the SIS-ECM patches in the right ventricular outflow tract position, stains for 
characteristic markers of cardiac muscle cells, endothelial cells, and cardiac fibroblasts 
were performed, as seen in Table 3.2. For all patches, cell proliferation was demonstrated 
by antibodies against proliferating cell nuclear antigen. Blood cells invading the tissue 
were identified by antibodies against CD45 (leukocyte common antigen). 
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Table 3.2 RVOT Patch IHC Markers and Their Function 
Sarcomeric alpha- Cardiac-specific marker that Abeam 1:25 
actin in attaches actin thin filaments to 
the z-line of the sarcomere 
contractile complex 
CD45 Membrane protein indicating Abeam 1:50 
differentiated hematopoetic 
cells 
Cardiac troponin I Cardiac-specific marker that Abeam 1:50 
binds to actin in the 
contractile complex 
Cardiac Troponin T Cardiac-specific marker that Abeam 1:50 
binds to actin in the 
contractile complex 
3.11.2 IHC Analysis 
After staining, samples were analyzed for staining intensity using ImageJ 
Software. Slides were scanned with a Pathscan Enabler IV (Meter Instruments, Houston, 
TX) at 7200 DPI in RGB color space. lmageJ was used to quantify staining intensity on a 
scale of0-255; them-file developed by Bagrat Grigoryan can be found in Appendix 3. 
Briefly, areas of each image containing overlapped tissue and tissue that was not adhered 
to the slide were removed for all analyses. For each slide, native tissue and patch areas 
were analyzed separately. Background subtraction and color correction were used with 
the rolling ball method (pixel radius 150 mm, light background, sliding paraboloid). An 
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algorithm developed by Ruifrok and Johnston was used to deconvolute the image, and a 
built-in vector for hematoxylin and DAB (H DAB) was used to separate the image into 
respective vector colors.93 Using the red color vector, the lower threshold was set to 0 
and the upper threshold was set to the value obtained when either the native tissue or the 
patch area from the negative control image became undetectable. The image was 
converted into a binary mask, and small holes were filled. Parameters were set to analyze 
regions of interest within a specified range (size 40-infinity, circularity 0.00-1.00), and 
the results containing the mean and area of each region of interest were exported to 
Microsoft Excel for further analysis. 
The total intensity stained was calculated using the equation 
l:(m; •aJ 
I a, 
where mi is the mean region of interest stained and ai is the area stained. 
3.12 Statistics 
All statistical analyses were conducted using SigmaPlot 12.0 (Systat Software Inc, 
San Jose, CA). Data are presented as mean and standard deviation. Two-way multi-
factorial analysis of variance (ANOVA, nonparametric) was used to compare native 
versus patch sections at 5 and 8 months for all IHC, extensibility, and muscle fiber 
diameter comparisons. One-way ANOV A testing was also used to compare 
neovascularization of the patch at 5 months versus 8 months, and native versus patch 
elastic modulus at 5 and 8 months. Post-hoc testing was used for sub-group comparisons. 
The level of significance was set at a=0.05 
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Chapter 4: Results of an RVOT Patch Implanted in a Juvenile Ovine Moder 
4.1 Animals and surgical procedure 
All4 animals survived the surgical procedures and follow-up period, and were included 
in the study. Study animals were sacrificed at postoperative days 143, 174, 237, and 244. 
4.2 In vivo epicardial echocardiography 
Epicardial echocardiography was performed in all 4 study animals. This technique 
showed that the patch region contracted with the native myocardium, with thickening of 
the patch region seen during systole (Fig 4.1). 
Figure 4.1 Epicardia] echocardiogram of SIS-ECM implanted sheep hearts (stiJJ). Note thickening of 
region of patch (arrowhead) during systole. LV = left ventricle. RV = right ventricle. 
2 The majority of this and the previous chapter are being prepared for submission to The 
Journal ofThoracic and Cardiovascular Surgery and will be published as Scully BB, Fan 
C, Grigoryan B, Jacot JG, Vick GW, Kim J, Fraser CD, Grande-Allen KJ, and Morales 
DLS. In Vivo Remodeling of an Extracellular Matrix Patch into Functional Myocardium 
in an Ovine Model. 
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4.3 In Vivo Contact Electrical Mapping 
Contact electrical mapping showed a coordinated electrical signal across the SIS-ECM 
patch at both 5 and 8 months (Fig 4.2). The amplitude of the signal averaged from the 
patch at 5 and at 8 months was not significantly different than the signal from the native 
neighboring ventricular tissue (4.38 ± 0.373 mV vs. 4.834 ± 0.617 mV, p = 0.639 at 5 
months and 1.54 ± 0.167 mV vs. 1.34 ± 0.168, p = 0.052 at 8 months). 
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Fig 4.2: In vivo electrical contact mapping ofSIS-ECM implanted in sheep right ventricle. (Above) Trace 
at 5 months. (Below) Trace at 8 months. 
4.4 Optical mapping 
Of the 4 hearts studied, Langendorff perfusion with subsequent paced beating was 
successful in one heart from each time point. Optical mapping showed that the electrical 
signal was being conducted across the patch, both at 5 and 8 months. Fourier-transform 
analysis revealed a peak frequency at 1 Hz in the middle of the patch at both time points, 
corresponding to the stimulating frequency. Time-shift activation maps showed 
continuity of electrical signal across the RVOT, including the patch region, at both time 
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points (Fig. 4.3). 
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Fig 4.3: Optical mapping analysis. The temporal activation of the heart is shown at 5 months (A) and 8 
months (B) post-implantation, with similar conduction to that of native tissue a1ong the epicardial layer of 
the SIS-ECM patch. Color scale is identical in both images and shows the difference in temporal activation 
measured from the apex calculated after Fourier analysis. Circles indicate location of the SIS-ECM patch. 
Scale on righthand side is in seconds. 
4.5 Mechanical testing 
Prior to implantation, the SIS-ECM patch material had an elastic modulus of 42.9 
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± 11.6 MPa, which decreased to 1.28 MPa ± 0.9 at 5 months, and to 0.976 ± 0.3 MPa at 8 
months (Fig. 4.4). There was no statistical difference between the stiffness of the SIS-
ECM measured at 8 months and the neighboring native right ventricle tissue (0.976 ± 0.3 
vs. 0.614 ± 0.2 MPa, p=0.333). The extensibility ofSIS-ECM and native ventricular 
tissue was not significantly different at either 5 or 8 months (23 .1 ± 7. 7% for native tissue 
versus 24.3 ± 12.6% (p=0.928) at 5 months and 21.6 ± 3.1% (p=0.384) at 8 months for 
patch). 
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Fig 4.4: Comparison ofYoung' s modulus in SIS-ECM implanted hearts versus native myocardium. 
Logarithmic scale used to report elastic modulus. 
4.6 Strain Mapping 
Strain mapping was performed concurrently with mechanical testing. Strain 
mapping was challenging in this application due to the difficulty of applying the charcoal 
grid and the variation in color of the tissue. In addition, the points at the edges of the 
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tissue were easily distorted as the tissue was pulled to tension, which can be explained in 
part by Saint Venant' s Principle, which states that the stresses, strains and displacements 
far from the ends of a rod or beam subjected to end loading depend only on the resultant 
forces and moments acting on its ends. The material heterogeneity was thus not captured 
as well as we had hoped; however the results do show a less uniform strain throughout 
the patch when compared to native tissue, suggesting that remodeling is occurring at 
different rates in the transition regions compared to the center. Heterogeneity of strain is 
suggested by the strain maps obtained, however with a larger sample size clearer links 
may emerge between strain patterns and material remodeling. 
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Figure 4.5 Strain Mapping was performed concurrently with mechanical testing. and demonstrated greater 
anisotropy in the patch when compared to the native tissue. Representative images are shown. A) Patch 
placed in the RVOT at 5 months. B) Native RVOT. 
4.7 Histology and IHC 
Gross visual assessment of the patched hearts at 5 months was suggestive of 
bioresorption (Fig. 4.6, A-B). At 8 months, the patch thickness approached that of the 
native tissue (Fig. 4.6, C). By 8 months, gross muscle was visible inside the suture line 
(Fig. 4.6, C-D). It was also observed that the healed regions at both time points were in 
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the circular shape of the original patch, as opposed to a straight line, which was the shape 
of the slit incision in the RVOT. 
Fig 4.6: Gross visual assessment of implanted SIS-ECM patch material. A) 5-month sample with 
ruler for size reference. B) 5-month sample with black arrows pointing to perimeter of patch. C) Side 
view of patch thickness. Arrows point to top and bottom of patch pre (right) and post-implant (left). 
D) 8-month sample with black arrows point to scarring at patch circumference. Gross muscle can be 
seen inside patch. Photos taken by author. 
Histological analysis of tissue samples at 5 and 8 months revealed evidence of 
neovascularization and formation of organized muscle cell islands within the SIS-ECM 
patch (Fig. 4.7, A, B), with cells seen throughout the patch area (Fig. 4.7, C). 
Furthermore, degrading sutures were easily identifiable at both 5 and 8 months. 
Degrading PDS material could be seen in circular areas underneath the microscope (Fig. 
4.7 A and C). 
Neovascularization was 3.5 times greater at 5 months compared to 8 months (Fig. 
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4.7, D) as measured by number of vessels per area (3.08 ± 1.2 vessels/mm2 versus 0.88 ± 
0.3 vessels/mm2, respectively, p = 0.004). By 8 months, muscle fibers inside the patch 
stained positive for cardiac muscle markers, such as Troponin I (Fig. 4. 7, E). Muscle 
fiber organization appeared to have increased at 8 months as compared with 5 months, 
with the corresponding appearance of fascicle-like structures (Fig. 4.7, F-H). At 8 
months, muscle fiber diameter between patch and native tissue was not statistically 
different (12.5 ± 2.6 vs. 9.7 ± 2.4 J..lm, p = 0.059). No evidence of calcification was 
observed at 5 or 8 months, as apparent from the absence of alizarin red staining (Fig. 4.8, 
F). 
Fig 4.7: Histological analysis ofSIS-ECM patch implanted in RVOT. Movat's Pentachrome stains (A-D): 
A) neovascularization in 5-month tissue samples (black arrows). B) muscle-cell islands in 5-month sample 
(black arrows). C) cell infiltration into center of patch at 5 months. Circular dotted lines show degrading 
PDS suture material. D) neovascularization (black arrows) and muscle fiber organization at 8 months. E) 
gross muscle remodeling inside suture lines (dotted lines) at 8 months with Troponin I stain. Masson's 
Trichrome stain (F-H): F) native ventricle muscle fibers at 8 months. G) patch muscle fibers at 8 months. 
H) patch muscle fibers demonstrating alignment at 8 months. IHC stains (I-L): I) sarcomeric alpha actinin 
stain at 8 months. J) Cardiac troponin T stain at 8 months. K) Cardiac troponin I stain at 8 months. L) 
CD45 stain at 8 months. Black bars: 400 microns. 
41 
IHC staining with antibodies against sarcomeric alpha actinin, troponin T, and 
troponin I revealed intense staining in the patch area (Fig. 4.7, I-K and Fig. 4.8 C-E) 
confirming that the cells demonstrated a cardiac myocyte phenotype. Similar results were 
obtained with antibodies against CD45 (Fig. 4. 7, L and Fig. 4.8, B), indicating the 
hematopoietic origin of these muscle cells. There was no staining in the negative-control 
slides (Fig. 4.8, G-J). For sarcomeric alpha actinin, CD45, troponin I and troponin T, the 
difference in staining intensity between the native tissue and patch decreased from 5 
months to 8 months (Fig 4.8; A-D, refer to Table 4.1 for results of significance testing). 
The staining intensity of sarcomeric alpha actinin was significantly higher in the patch 
compared to the native ventricle at 5 months (p=0.003), but not at 8 months (p=O. 789). 
Similarly, the staining intensities of troponin I and troponin T were significantly higher in 
the patch at 5 months (p=0.004 and 0.022 respectively), but not at 8 months (p=O.l86 and 
0.666, respectively). There was no significant difference between the staining intensities 
of CD45 between the patch and the native ventricle at either 5 months or 8 months. 
F G J 
Fig 4.8: lliC images ofSIS-ECM patch implanted in RVOT at 8 months. A) Movat's pentachrome stain of 
RVOT patch at 8 months for comparison. B) CD45. C) Sarcomeric alpha actinin. D) Cardiac Troponin I. 
E) Cardiac Troponin T. F) Alizarin red stain. G)-J) corresponding negative controls beneath antibody-
stained slides B)-E). 
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Fig. 4.9. IHC analysis: Graphs of staining intensity (area of interest, normalized to background 
staining). Black columns represent native tissue and white columns represent patch tissue. Asterisks 
denote statistical significance between columns (p < 0.05). P-values from 2-way ANOV A analysis 
are shown in Table 1. A) Sarcomeric alpha actinin. B) CD45. C) Troponin I. D) Troponin T. 
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Table 4.1: Immunohistochemistry comparisons in staining intensity of patch material and 
native myocardium at 5 months and 8 months. P values in bold indicate a significant 
difference. 
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Sarcomeric alpha 
actin in 
132.4±21.37 111.3±12.3 p = 
0.003 
103.1±15.2 100.0±21.0 p = 0.789 
CD45 152.5±17.8 142.9±14.9 p= 133.0±16.0 124.1±15.9 p = 0.328 
0.181 
Troponin I 159.8±26.5 98.6±23.6 p= 108.2±33.2 137.8±28.7 p = 0.186 
0.004 
Troponin T 151.9±13.5 112.8±27.4 p= 131.2±20.2 125.8±24.2 p = 0.666 
0.022 
• Comparison is patch versus native tissue at 5 months 
** Comparison is patch versus native tissue at 8 months 
4.8 Discussion 
4.8.1 Histologic evidence of constructive myocardial remodeling 
The goal of this study was to evaluate, by multiple approaches, the utility of the 
juvenile ovine model for the assessment of remodeling of SIS-ECM implanted in the 
RVOT, and to compare the remodeled SIS to functional myocardium. The ovine model 
proved highly suitable for this study with all animals surviving the surgery, thriving post-
operatively for 5-8 months, and demonstrating well-defined regions of remodeling where 
the patch was implanted. The histological analysis of explanted tissue showed evidence 
of progressive, time-dependent tissue remodeling, with neovascularization, muscle-cell 
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island formation, and organization of muscle fibers, with eventual resorption of the patch 
and formation of fascicles (Fig. 4.5). Interestingly, vessel density was 3.5 times greater at 
5 months compared to 8 months. It is possible that more immature blood vessels were 
followed by fewer but more mature ones, or that as the cells became more differentiated, 
nutrient demand and therefore blood vessel requirement decreased, as more efficient 
metabolism has been reported necessary for cardiac differentiation of stem cells.94 In 
addition, comparison of muscle fiber diameter in the patch versus native tissue showed no 
difference at 8 months. Prior studies have shown significant differences between right 
ventricle muscle fiber diameter in hearts under different remodeling conditions, 
suggesting that muscle fibers in the patch are responding to similar loading conditions as 
those in the native ventricle.95 
IHC staining for sarcomeric alpha-actinin, troponin I, and troponin T was 
consistent with a cardiac muscle phenotype for the cells found within the patch (Fig 4.6, 
I-L). In addition, staining intensity increased between 5 and 8 months, with statistical 
differences between patched and native tissue observed at 5 months for sarcomeric alpha 
actinin, cardiac troponin I and T markers but no statistical difference seen at 8 months, 
demonstrating further remodeling with increasing time from implant. Importantly, the 
formation of islands of muscle cells occurred in the interior of the patch, and not just at 
the periphery. This is particularly interesting because the patch size used, 2 x 2 em, had a 
very large surface area. It has been previously reported that the maximum distance for 
cellular ingrowth from surrounding tissue into unseeded matrix scaffolding is 
approximately 0.5 cm.96 The presence of viable islands of differentiated muscle cells in 
the SIS-ECM patch and positive staining with CD45, a marker of hematopoietic origin, 
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suggests that some of the cells populating the SIS-ECM were derived from sources other 
than local myocardial progenitor cells. Other studies have shown that SIS-ECM 
degradation products are not only chemotactic,25•45 but attract c-kit positive cells,46 and it 
is therefore possible that the cells found within the borders of the patch are marrow-
derived. In addition, the muscle island was circular, more resembling the patch, as 
opposed to elongated as might be expected from a healed straight line slit. 
Also of interest in the histologic analysis was the absence of calcification, even at 
8 months. This finding is notable in that synthetic and bioprosthetic materials are 
notoriously prone to calcification in juvenile sheep, which usually occurs within 4 weeks 
of implantation.97 
4.8.2 Improvement in material elasticity 
Implanted surgical materials, such as Dacron, are known to maintain their high 
stiffness compared to native tissue over time. 98 In contrast, the mechanical stiffness of 
the SIS-ECM decreased over the course of the study, as measured by Young's modulus. 
By the 8-month time point, the material behavior of SIS-ECM had become statistically 
indistinguishable from that of the surrounding native tissue, having become less stiff and 
more extensible. This mechanical testing data provides evidence suggesting that the SIS 
has remodeled to resemble myocardium. An alternative explanation could be that there 
was no contribution of the SIS-ECM patch to the mechanical properties and that the 
native RVOT had healed on its own, but that there was some fibrosis of the myocardial 
tissue. The fibrosis would lead to increased stiffness and decreased extensibility of the 
myocardial tissue, such as is seen in heart failure9'J. However, due to the circular shape of 
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the remodeled region ofRVOT, it seems unlikely that there was no mechanical 
contribution from the SIS-ECM patch. Thus, the similarity between the patch and native 
tissue mechanical characteristics demonstrates a significant and functional remodeling 
process. 
4.8.3 Evidence of electrical conductivity 
The SIS-ECM showed unique and favorable bioelectrical properties consistent 
with significant cellular and functional remodeling. At 5 and 8 months, contact electrical 
mapping and optical voltage mapping both showed evidence that the implanted SIS-ECM 
patch was capable of transducing coordinated electrical signals. Furthermore, Fourier 
transform analysis identified the dominant and principal frequency in the middle of the 
patch to be 1 Hz, which was the frequency at which the heart was being paced. These 
findings are remarkable, given that other patch materials, such as native pericardium, 
bovine pericardium, PET, and ePTFE are electrically inert.100 
This functional data is also interesting in light of the fact that although cells 
staining positively for muscle markers such as sarcomeric alpha actinin, troponin I and 
troponin T were seen throughout the patch at both 5 and 8 months, mature muscle cell 
phenotypes were seen in islands rather than in a continuous stretch from one suture line 
to the other. The presence of islands supports invading cells differentiating; ifthe native 
myocardium had simply healed together, muscle cell phenotypes would be more 
continuous surrounding a middle straight line healed scar. The ECM has been shown to 
play a central role in transmitting mechanical forces, mediated by ECM-integrin-
cytoskeleton coupling.101 The electrical signals conducted across the patch in this study 
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suggest that SIS-ECM is capable of providing a suitable environment for the invasion and 
differentiation of cardiomyocytes. Further investigation will need to be done to further 
characterize the electrical signals transmitted over a remodeling patch, and to ensure that 
arrhythmias do not develop. 
4. 8. 4 Limitations and fUture directions 
A significant limitation of this study is the small sample size, confounded by the 
fact that only 2 of the 4 hearts were successfully reperfused for the optical mapping 
experiment. There was also no comparator patch material (such as Dacron or 
pericardium) used in the study. Although the Dacron patches would be incapable of 
remodeling, they would have provided an important comparison for the deposition of 
pannus on the patch material. 
Although the slit defect that we created allowed cell invasion and subsequent 
remodeling to take place, a critical size defect model, in which a portion of the native 
tissue would be removed prior to sewing in the ECM patch, may be a better choice for 
evaluating the remodeling of the patch in the future. A critical size defect model would 
have avoided the potential for the proximal tissue to re-anastomose, and allowed more 
initial tension to be placed on the implanted patch. While we do not believe that the 
tissue on either side of the slit defect re-anastomosed, based on the circular suture lines 
visible at both 5 and 8 months, a patch model that eliminates this possibility would 
considerably strengthen the results of related future studies. 
In addition, although this was not possible in this initial study due to the small 
numbers of animals, in future studies we would like to include both an earlier and a later 
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time point. The earlier time point would be used to study the inflammatory process, 
which is completed within 3 weeks in cardiac tissue and results in the formation of scar 
tissue by four weeks. 102 A later time point of one year would allow for further 
investigation into the patches' mechanical properties and contractility following a longer 
remodeling period. 
Nevertheless, these preliminary results showing functional electrical activity 
within the implanted patch are remarkable and, to our knowledge, unprecedented. This 
degree of remodeling has not been reported for any other patch material currently used 
for human cardiac repair. In the future, we intend to continue this line of investigation 
using a larger number of animals, a comparator arm (using native pericardium as control 
material), a 3D activation propagation map ofthe RV electrical activity, as well as 
advanced imaging to document the change in viability and functionality of the patch over 
time. 
4.8.5 The ECM and constructive remodeling: Build it and they will come1 
The field of tissue engineering has experienced a paradigm shift over the last 
decade as new evidence about the importance of the extracellular matrix in tissue 
remodeling and regeneration has become available.103 Where it was once thought that 
provision of sufficient numbers of pluripotent stem cells was the key to tissue 
regeneration, this idea has not met with success in practice. It is increasingly accepted 
that stem cells can only perform their regenerative function within a conducive 
microenvironment provided by a biochemically functional extracellular matrix.41 Indeed, 
3 This analogy is the brainchild ofDLS Morales. and was presented by him at BCM's Surgery Grand 
Rounds in February 2011. 
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adult tissues, such as mature myocardium, that were once thought to be mitotically 
senescent have been shown to contain tissue-specific progenitor cells that are capable of 
proliferation, maturation, and regeneration, given the proper environment. This 
phenomenon can be likened to a productive office building; even a large number of 
skilled office workers would be hard-pressed to act productively if housed in a building 
that lacked basic utilities, furnishings, telephones, and computers. Furnished with the 
appropriate tools, environment, and direction, however, just a few ofthese same workers 
could be capable of supporting a productive, growing and self-sustaining business. In this 
analogy, the extracellular matrix provides the proper environment, and the body provides 
stem cells -the ''workers" - that repopulate the matrix and transform it into healthy, 
functional tissue. This repopulation is likely to be particularly robust in children, who 
have a greater pool of pluripotent cells. 
4.8. 6 Conclusion 
In summary, the SIS-ECM patch, when surgically implanted in the juvenile ovine 
RVOT, demonstrates constructive remodeling into functional myocardium as evidenced 
by histological, mechanical, and electrical properties. Juvenile ovine appear a suitable 
model for evaluating the remodeling of an SIS-ECM patch implanted in the right 
ventricular outflow tract, allowing evaluation of conduction of an electrical signal, cell 
infiltration and phenotype, and remodeling extracellular matrix properties. Should future 
studies support these findings, this material may present an exciting new solution for 
cardiac grafting and tissue repair, especially in the pediatric population. 
Chapter 5: Results of an Aorta and Pulmonary Artery Patch 
Implanted in a Juvenile Ovine Model4 
5.1 Mechanical Testing 
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Prior to implantation, the SIS-ECM patch material had an elastic modulus of 42.9 ± 
11.6 MPa. In the descending aorta, this decreased to 2.88 ± 2.89 MPa at 5 months, and to 
3.185 ± 0.836 MPa at 8 months (Fig. 5.1). Native aorta had an elastic modulus of0.335 
± 0.019 MPa. 
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Figure 5.1 Comparison of Young' s modulus in SIS-ECM implanted in the descending aorta 
versus native aorta. Logarithmic scale used to report elastic modulus. 
4 The majority of this chapter is being prepared for submission and will be published as 
Scully BB, Grigoryan B, Fan C, Fraser CD, Grande-Allen KJ, and Morales DLS: In Vivo 
Remodeling of an Extracellular Matrix Patch in the Aorta and Pulmonary Artery 
Positions in an Ovine Model. 
In the main pulmonary artery, the elastic modulus decreased to 5.627 ± 4.234 MPa at 5 
months, and to 4.833 ± 0.243 MPa at 8 months (Fig. 5.2). 
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Figure 5.2 Comparison ofYoung' s modulus in SIS-ECM implanted in the main PA versus 
native PA. Logarithmic scale used to report elastic modulus. 
5.2 Strain Mapping 
Strain mapping was performed concurrently with mechanical testing. Many of 
the same challenges that prevented a sufficiently precise analysis of the material 
heterogeneity in the RVOT patch samples were faced with the vascular tissues as well. 
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In the aorta, as with the RVOT, strain appeared more heterogeneous in the patch (Fig. 5.3 
A, C) when compared to native tissue (Fig. 5.3 B,D), and this heterogeneity was observed 
for both time points. In the P A, there was less difference observed between the patch 
(Fig. 5.3 E) and the native tissue (Fig. 5.3 F). 
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Figure 5.3 Representative Strain Mapping images from the Aorta and PA patch positions. A) Taken from 
aorta patch at 5 months. B) Native aorta at 5 months. C) Aorta patch at 8 months. D) Native aorta at 8 
months. E) PA patch at 5 months. F) Native PA at 8 months. 
5.3 Histology 
At both 5 and 8 months, the patch had integrated well into the surrounding tissue in 
both the aortic and pulmonary artery positions. Figure 5.4 shows the gross dissection of 
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the patch and surrounding tissue in both locations. The patch was aneurysmal at both the 
aortic and pulmonary artery locations. 
Figure 5.4 Gross dissection of aorta and PA patches at eight months. White arrows mark patch edges. A) 
Descending aorta patch, adventitia side. B) Descending aorta patch, intima side. C) Main pulmonary artery 
patch, intima side. D) Main pulmonary artery patch, adventitia side. E) Descending aorta dissected into 2-
mm wide strips for mechanical testing and tissue fixation. Sections containing patch are 4th, 5th, and 6th 
from the left. F) Main pulmonary artery dissected into 2-mm wide strips. Sections containing patch are 3rd, 
4th, and 5th from the left. Photos taken by author. 
Histologic analysis of both the aortic and P A patches showed significant 
remodeling by 5 months. In the aorta at 5 months, cells could be seen throughout the 
patch, neovascularization has begun, and staining for elastin and glycosaminoglycans 
(GAGs), matrix components that were not found in the pre-implanation patch, was 
evident (Fig. 5.5 A-Band D-E). By 8 months, vessel layers were more defined, the 
transition regions (the tissue immediately adjacent to the suture line) had become less 
distinct, and the vessels had more elastin and muscle staining (Fig. 5.5 C, F). 
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Figure 5.5 Histologic evaluation of the SIS-ECM patch placed in the descending aorta. Patch only 
sections are shown with transition regions of patch and native tissue directly below. A) Masson's 
trichrome stain of the patch placed in the aortic position at 5 months. Cells can be seen throughout as well 
as heavy staining of collagen (blue). B) Movat's pentachrome stain of aortic patch at 5 months. Layering 
is beginning to be seen with stronger collagen staining of the adventitia side (yellow). C) Movat's 
pentachrome of aortic patch at 8 months. More well-defined layers have formed, with an elastin-staining 
layer (black), collagen layer (yellow), and muscle staining layer (red). D) Masson's of transition region 
between native tissue and patch (degrading suture can be seen in the middle). Native tissue (on left) shows 
greater muscle staining (red). E) Movat's pentachrome stain of transition region at 5 months. Elastin stain 
(black) clearly differentiates the native tissue from the patch. F) By 8 months, the tissue directly adjacent 
to the suture line is less defined, as more elastin staining can be seen inside the patch. 
In the pulmonary artery at 5 months, neovascularization was already apparent and cells 
could be seen throughout the patch (Fig. 5.6 B,C, F,G). The patch stained for not only 
collagen, but also elastin (black) and glycosaminoglycans (blue-green) (Fig. 5.6 C,G). In 
contrast, prior to implantation, the patch was almost completely collagen staining 
(yellow) and could clearly be differentiated from the native tissue (Fig. 5.6 A,E). By 8 
months, patch (Fig. 5.6, H) resembled native tissue (Fig. 5.6, D), with both staining well 
for muscle (reddish purple) and elastin (black). 
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Figure 5.6 Histologic evaluation of the SIS-ECM patch placed in the main PA. Transition regions where 
the patch and native tissue meet are shown at the top with patch only sections below. A) and E) Movat' s 
pentachrome stain of patch and native tissue prior to implantation. B) and F) Masson' s trichrome staining 
of transition region and patch, respectively at 5 months. C) and G) Movat' s pentachrome stain of transition 
region and patch at 5 months. D) Movat' s pentachrome stain of native PA compared to H) patch. 
5.4 Immunohistochemistry 
IHC staining for endothelial lipase gene (LIPG), lysyl oxidase (LOX), smooth 
muscle alpha actin, matrix metalloprotease (MMP) 1, and calponin h 1 was performed, 
and revealed strong staining of the patch in both the aortic and P A positions at 5 and 8 
months. There was no staining in the negative-control slides. The difference in staining 
intensity between the patch and native tissue at both 5 and 8 months was measured and 2-
way ANOV A performed (see tables 5.1 and 5.2 for results of significance testing). 
Interestingly, no statistically significant difference was found between patch and native 
tissue in either the aorta or P A at both 5 and 8 months. 
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Table 5.1 Immunohistochemistry comparisons in staining intensity of patch material and 
native P A at 5 months and 8 months. 
K·:~·:)~r:~=::::::~·~"~.··. ::. · ... ,: . :. :.:. ::,_~~:· .: :·--: !.·. :~.· .. ~ .... : ..... : ._~. : •... · .:: .... ~_-~:~_; 
LIPG 110.6±51.88 110.6±57.19 p= 0.5 126.88±38.46 123.9±34.0 p = 0.55 
LOX 122.5±40.8 129.6±13.3 p= 0.676 109.9±17.7 122.5±26.4 p = 0.627 
Smooth muscle 141.8±51.5 109.0±51.3 p = 0.854 141.9±27.2 138.6±22.5 p = 0.565 
alpha actin 
MMP1 130.7±49.4 140.7±49.4 p = 0.363 136.9±43.9 117.3±51.6 p= 0.740 
Calponin h1 118.0±24.6 113.0±29.5 p= 0.642 106.0±15.3 112.1±9.25 p = 0.325 
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Table 5.2 Immunohistochemistry comparisons of staining intensity of patch material and 
native aorta at 5 months and 8 months. 
~':· -· -.:Nji::r:',~.:,~:·-. ~,~: ·::.:::: :,,)_/L. ··; ·. I. ; :•·, .: ~:, .. ~:.:~,_. :_ -~ _:: ~:.·:_.:. J 
LIPG 87.3±28.5 85.3±21.6 p = 0.537 98.1±34.0 99.3±27.3 p = 0.482 
LOX 141.3±23.7 147.1±17.5 p = 0.342 119.2±11.1 101.6±25.0 p = 0.927 
Smooth muscle 146.0±29.8 130.8±42.6 p = 0.786 134.2±11.2 139.5±8.19 p = 0.364 
alpha actin 
MMP1 157.8±45.1 127.4±46.2 p = 0.834 117.7±37.9 120.3±34.4 p = 0.456 
Calponin h1 156.2±22.5 137.1±31.4 p = 0.731 109.6±4.67 115.2±23.7 p = 0.376 
These immunostaining results suggest that several cell migration/differentiation 
and matrix production processes were well underway in the remodeling patch. LIPG has 
phospholipase and triglyceride lipase activity and binds heparin; it is expressed in 
coronary artery endothelial cells. Its presence in both the patch and native tissue in the 
aortic and P A positions suggests that the patch had remodeled to have an endothelial 
tissue component such as a neo-intima or vasa vasorum. 
Lysyl oxidase is a cross-linking enzyme in collagen and elastin synthesis. Its 
presence in both the patch and native tissue in both the aortic and P A positions suggests 
that new collagen and elastic fibers are being synthesized by cells that have invaded the 
patch. 
58 
Smooth muscle alpha actin is expressed by smooth muscle cells, and staining for 
this smooth muscle cell marker was found in both patch and native tissue in the aorta and 
PA. lbis suggests that cells within the remodeled matrix had a smooth muscle 
phenotype, a result further supported by staining for calponin h 1, which stabilizes the 
actin network in vascular smooth muscle cells and is a maker of their contractile ability. 
Finally, matrix metalloprotease-1 (MMP-1) is an enzyme important in matrix 
degradation. Staining for this enzyme suggests that active extracellular matrix turnover 
was taking place in the patch in both the aorta and PA. 
5.5 Discussion 
5.5.1 Improvement in material elasticity 
Many types of implanted surgical materials, such as Dacron, are known to 
maintain their high stiffness compared to native tissue over time.98 In contrast, the 
mechanical stiffness of the SIS-ECM implanted in the aorta and PA decreased 
significantly over the course of the study, as measured by Young's modulus. While the 
elastic moduli of both the aortic and PA patches did not decrease as much as that seen in 
the RVOT patch, they did approach the elastic moduli of the surrounding native tissue. 
The lower magnitude change in the vascular patches compared to the RVOT patch may 
have been due to the inherently higher collagen content and elastic moduli of blood 
vessels compared to the RVOT. If the SIS-ECM had been explanted at longer time 
points, the elastic modulus of patch in the aortic and PA positions may have become even 
closer to that of native tissue. 
Interestingly, the aorta patch appeared to have greater heterogeneity of strain 
compared to the PA patch; this heterogeneity may have been due to the increased 
systemic pressures experienced by the patch in the aortic position. As with the RVOT 
patch, heterogeneity of strain was suggested by the strain maps, however with a larger 
sample size clearer links may emerge between strain patterns and material remodeling. 
5.5.2 Histologic evidence of vessel remodeling 
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The goal of this study was to evaluate the suitability of the juvenile ovine model 
for a multi-faceted analysis of the ability of SIS-ECM implanted in the aorta and 
pulmonary artery positions to remodel into functional vasculature. The histological 
analysis of tissue explanted from these ovine models showed evidence of progressive, 
time-dependent tissue remodeling, with neovascularization, cell invasion, increased 
staining of elastin and smooth muscle, and eventual resorption of the patch (Fig. 5.5 and 
5.6). Interestingly, distinct layers could be seen at 5 months and became more defined by 
8 months, particularly in the aortic position. This layered structure was particularly 
interesting in light of the three-layer structure of the native vessel (adventitia, media, and 
intima). The increase in staining for elastin and smooth muscle at 8 months suggests that 
the implanted patches are remodeling in response to the physiological loading 
environment as well as in response to the surrounding vasculature. Remarkably, the 
remodeled patches in the aortic and PA positions have remodeled to resemble the 
surrounding tissue, and at both 5 and 8 months look significantly different than their 
RVOT patch counterparts. The greater degree of remodeling at 8 months suggests that 
further remodeling to resemble functional vasculature would take place if the patches 
were explanted at a later time point. 
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At 5 and 8 months, the patch was found to be anewysmal at both the aortic and 
pulmonary artery locations; this shape was likely due to a combination of the thinness of 
the tissue and the high magnitudes of pressure experienced in the vessels .. Given that the 
2x2 em patch was sewn into the vessel following a full thickness linear cut without any of 
the tissue being removed, the anewysmal nature of the remodeled patch was a clear 
demonstration that the wound did not simply re-oppose. 
Also of interest in the histologic analysis was the absence of calcification for both 
aortic and PA patches (as in the RVOT), even at 8 months. This :fmding is notable in that 
synthetic and bioprosthetic materials implanted in juvenile sheep are notoriously prone to 
calcification, which can occur within 4 weeks of implantation.97 
5.5.3 Limitations and .future directions 
As described in detail in the RVOT chapter, a significant limitation of this study 
is the very small sample size. Nevertheless, these preliminary results show an impressive 
and time-dependent remodeling of an SIS-ECM patch implanted in both the aortic and 
P A positions. Larger sample sizes and control groups are needed to further investigate 
the potential of this novel cardiovascular patch. 
5.5.4 Conclusions 
In summary, we have found that an SIS-ECM patch, when surgically implanted in 
the ovine aorta and P A, is capable of constructive remodeling into functional vascular 
tissue as evidenced by histological and mechanical properties. Juvenile ovine appear a 
suitable model for evaluating the remodeling of an SIS-ECM patch implanted in the aorta 
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and P A, allowing evaluation of cell infiltration and phenotype and remodeling 
extracellular matrix properties. Should future studies support these findings, this material 
may present an exciting new solution for cardiac grafting and tissue repair, especially in 
the pediatric population. 
Chapter 6: Research Design and Methods: In Vitro Study5 
6. 1 Scaffold preparation 
Decellularized porcine SIS-ECM (CorMatrix©) was cut into strips measuring 
3.18x0.64 em (length x width). Pepsin-treated SIS-ECM strips were digested using 2 
mg/mL pepsin solution (50 mg pepsin from porcine gastric mucosa and 025 mL 1 N 
hydrochloric acid in 24.75 mL di water) for four hours under agitating conditions. 
Untreated SIS-ECM strips were soaked in DMEM medium containing 1% antibiotic 
solution for four hours. Cell seeded samples were statically seeded with third passage 
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porcine mitral VICs at a cell density of 15 x 106 cells/cm2 and incubated for five days at 
370C in a rubber mold, cut to hold four SIS-ECM strips in a glass petri dish; each SIS-
ECM strip was covered with 0.6 mL of cell suspension. Mitral VICs were harvested as 
described by Gupta et al104• Media was changed every 1-2 days. Unseeded samples were 
incubated in medium for five days at 370C in the same type of mold. Using 4-0 Prolene 
suture, dynamic samples were then sewn into the middle module of the "splashing" 
mechanical stimulation bioreactor system previously described by Barzilla et al (see 
section 6.2i7• A volume of 4.5 mL medium was added and the bioreactor was placed in 
a 37°C incubator for seven days with media being changed every 1-2 days. Samples 
without mechanical stimulation were floated in medium in sterile, plastic petri dishes and 
incubated at 370C for seven days. 
5 The majority of this and the following chapter are being prepared for submission to The 
Annals of Biomedical Engineering and will be published as Scully BB, Grigoryan B, 
Erskine K, Fan C, Durst C, Kwak M, Barzilla J, Morales DLS, and Grande-Allen KJ. 
Evaluation of Matrix Degradation of a Small Intestinal Submucosa Patch Seeded with 
Mitral Valvular Interstitial Cells: An In Vitro Study. 
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6.2 Pepsin Optimization 
In order to optimize the pepsin concentration used for enzymatic pretreatment of 
SIS-ECM, mechanical testing was performed on SIS-ECM treated with pepsin solution 
with a range of concentrations from 0.015-0.1 wt % and shaken in pepsin solution for 
varying time points of 1, 2, 4, 8, 12, 24, and 32 hours. 
6.3 Bioreactor Setup 
A splashing bioreactor designed by Barzilla et al was used to provide gentle 
cyclic stretch and perfusion to the SIS-ECM.27 Used medium was plated on agar to 
verify maintenance of sterile conditions in the rotating system. In this system, the SIS-
ECM is mounted diagonally across the middle of the three modular segments, and the 
entire chamber is assembled then rotated through 360 degrees continuously for the 
culture duration, forcing the cell culture media to splash around the SIS-ECM on both 
sides [see Figure 6.1]. Because an excess length of the SIS-ECM is sewn into the 
bioreactor, the majority of the tissue section hangs loosely and is thus subjected to 
periodic flexure and stretch-induced perfusion with every rotation of the system. Oxygen 
delivery to the cells is maintained via a tissue flask cap with a thin porous membrane in 
its center that allows permeation of outside air, while protecting against contamination. 
Fig. 6.1 From Barzilla et al. a) Splashing bioreactor chamber comprised of three hollow segments into 
which the scaffold is mounted (at ANN and CH). Media inside the chamber provides nutrients for the 
cells seeded on the scaffold. b) The chamber is rotated 360 degrees at 0.33 revolutions per second, 
allowing media to splash over the scaffold surfaces. 
6.4 Mechanical Testing 
64 
After incubation and with or without dynamic treatment, the SIS samples were cut 
in half widthwise; half of the sample was used for mechanical testing and the other half 
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was analyzed with histology and immunohistochemistry. For mechanical testing, the 
SIS-ECM sample was blotted with bibulous paper to remove excess moisture from 
medium. The sample's width and thickness were measured in three positions and each 
was averaged. The ends of each length of sample were then super glued into a balsa 
wood mount, cut specifically for the sample. The balsa wood mounts were screwed into 
the clamps of the Enduratec 3200 mechanical tester (Bose Corporation, Eden Prairie, 
MN), and the sample was pulled to a taut length, bearing 0 N load. The length between 
clamps (gauge length) was measured. Mechanical testing was initiated by first 
preconditioning the sample, which included 10 cycles of increasing stretch and 
relaxation. The sample was then pulled to 55% of gauge length at a rate of 0.15 mm/sec. 
The Young's elastic modulus and extensibility were calculated from the load and 
displacement data by calculating the slope of the linear portion of the stress-strain curve 
and its x-intercept, respectively. 
6.5 Strain Mapping 
Strain mapping was performed on pepsin treated and cell seeded samples as 
described previously, using charcoal markers and digital image correlation code. 
6.6 Histology 
Histology was performed to determine the overall microstructure of extracellular 
matrix within the SIS-ECM samples, as well as the occurrence of cell remodeling. 
Hematoxylin and eosin, Movat's pentachrome, Masson's trichrome, and a hematoxylin 
and saffron stain (to look specifically at cell nuclei and collagen alignment) were 
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performed to demonstrate SIS-ECM structure and thcr location of extracellular matrix 
i 
components including collagen type I, highly hydrattfd glycosaminoglycans and 
i 
proteoglycans, elastic fibers, and smooth muscle. 
6. 7 Immunohistochemistry 
Immunohistochemical analysis was performe to identifY markers associated with 
valvular interstitial cell activation (smooth muscle al ha actin), cell proliferation--
specifically the early 01 phase and S phase of the c ll cycle (PCNA), and cell adhesion 
and migration processes (fibronectin), as shown in T ble 6.1. Slides were rehydrated and 
antigen retrieval performed (AR in PBS, 800C for 30 min), then sections were blocked 
with 10% goat serum buffer (Sigma, St. Louis, MO) d incubated for 1 hour at 37°C 
with primary antibodies against the markers in table .1. After rinsing in phosphate-
buffered saline, biotinylated secondary antibodies (J ckson Immunoresearch, West 
Grove, PA) were applied for 1 hour at room tempera . Positive staining was then 
demonstrated by a chromogen reaction using V ec · n Elite ABC and diaminobenzidine 
hematoxylin. Eliminating administration of the prim antibody created negative 
control samples for all markers. 
Analysis of staining intensity was performed previously outlined using ImageJ. 
67 
Table 6.1 SIS-ECM Patch IHC Markers and Their Function 
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Smooth muscle Expressed by smooth muscle Abeam 1:1000 
alpha actin cells (early stage marker for 
this phenotype) 
PCNA An auxiliary protein of DNA Abeam 1:2000 
polymerase delta involved in 
the control of eukaryotic DNA 
replication. 
Fibronectin Binds cell surfaces, involved in Abeam 1:100 
cell adhesion and motility 
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Chapter 7: Results of Matrix Degradation of a Small Intestinal Submucosa Patch 
Seeded with Mitral Valvular Interstitial Cells and Cultured in a Bioreactor6 
7.1 Pepsin Optimization 
Mechanical testing ofSIS-ECM treated with pepsin solution with a concentration 
ranging from 0.015-0.1 weight% and time points of 1, 2, 4, 8, 12, 24, and 32 hours 
demonstrated a substantial loss of stiffness after 4 hours in all of the tested concentrations 
(Figure 7.1). By 32 hours, the SIS-ECM separated into 4 distinct layers and became 
overly difficult to handle. 
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Figure 7.1 : The elastic modulus of the SIS-ECM decreased over time, with the majority of stiffuess lost 
after 4 hours. Graph created and pepsin optimization conducted by Minsuk Kwak, B.S. 
6 The majority of this and the preceding chapter are being prepared for submission to The 
Annals of Biomedical Engineering and will be published as Scully BB, Grigoryan B, 
Erskine K, Fan C, Durst C, Kwak M, Barzilla J, Morales DLS, and Grande-Allen KJ. 
Evaluation of Matrix Degradation of a Small Intestinal Submucosa Patch Seeded with 
Mitral Valvular Interstitial Cells: An In Vitro Study. 
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7.2 Cell Seeding 
Seeding of the SIS-ECM was verified using hematoxylin and eosin staining 
(Figure 7.2). In the pepsin-treated SIS-ECM, cells were seen both forming a layer on the 
surface of the SIS-ECM as well as invading into the deeper layers of the tissue. 
Figure 7.2: H&E stain demonstrating successful cell seeding ofSIS-ECM scaffold after five days of 
seeding. A) MVICs formed a neolayer on the surface of the scaffold and B) could be seen having 
infiltrated several layers into the tissue (black arrow) 
7.3 Mechanical Testing 
Untreated SIS-ECM had an elastic modulus of 42.9 ± 11.6 MPa. When comparing 
pepsin digested, cell seeded groups with and without mechanical stimulation after one 
week, there was a statistical difference between groups (11 .8 ± 5.1 MPa vs. 38.5 ± 10.9 
MPa, respectively) (Fig. 7.2). However, there was no statistical difference between the 
stiffness of the acellular pepsin-digested groups with and without mechanical stimulation 
(23.5 ± 18.5 vs. 34.7 ± 13.7 MPa, respectively). Likewise, the cell-seeded undigested 
group did not demonstrate statistical difference between groups with and without 
mechanical stimulation (38.7 ± 25.6 MPa vs. 26.0 ± 10.7 MPa, respectively). When 
comparing all of the groups without mechanical stimulation, the pepsin digested, cell 
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seeded scaffolds were significantly less stiff than the other 2 groups. However, there was 
no difference between the mechanically stimulated groups. 
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Fig. 7.3 Comparison ofYoung's modulus in static (without mechanical stimulation) versus 
dynamic (with mechanical stimulation) groups. The asterisk denotes statistical significance for the pepsin 
digested, cell seeded group without mechanical stimulation. 
The extensibility was generally higher in the statically cultured groups (without 
mechanical stimulation) when compared to the dynamic groups. For pepsin digested and 
cell-seeded SIS-ECM, the group without mechanical stimulation had an extensibility of 
9.62 ± 13.01% versus 4.82 ± 4.93% for the dynamic group. For SIS-ECM that was 
pepsin digested only, the group without mechanical stimulation had an extensibility of 
15.48 ± 10.69% versus 10.71 ± 13.87% for the dynamic group. For SIS-ECM that was 
cell seeded only, the group without mechanical stimulation had an extensibility of 14.45 
± 9.23 %, versus 13.17 ± 9.91% for the dynamic group. None of these differences were 
found to be statistically significant. 
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7.4 Strain mapping 
Strain mapping was performed on pepsin-treated and cell seeded dynamic SIS, 
cell-seeded only dynamic SIS, and pepsin-treated floating controls. Tissue in the pepsin-
treated and cell seeded dynamic group appeared more homogenous than expected when 
compared to cell-seeded alone; it is possible that the pepsin treatment leads to decreased 
heterogeneity, as the pepsin-treated control group also appears to have largely 
homogeneous strain. As found in the in vivo strain mapping, material heterogeneity was 
not captured as well as might be expected with a denser charcoal grid or a larger sample 
SIZe. 
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Fig. 7.4 Strain mapping results for A) pepsin-treated and cell seeded dynamic SIS-ECM, B) cell-seeded 
only dynamic SIS-ECM, and C) pepsin-treated floating controls. 
7.5 Histology 
Untreated SIS-ECM patches stained mostly for collagen (yellow) with some 
GAGs (blue-green) by Movat's pentachrome stain (Fig. 7.5 E) and space between distinct 
layers was visible. Pepsin pretreatment and mechanical stimulation led to greater tissue 
cohesiveness as seen by hematoxylin and saffron stain (Fig. 7.5 B & F). Without pepsin 
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pretreatment, the cell-seeded mechanically stimulated group showed less tissue 
cohesiveness, although cells were able to invade the first few layers of the SIS-ECM 
patch (Fig. 7.5 C & G). Pepsin pretreatment and cell-seeding prior to mechanical 
stimulation resulted in SIS-ECM patches that demonstrated the most tissue cohesiveness 
as well as the deepest penetration of the MVICs into the middle of the patch (Fig. 7.5 D 
&H). 
Fig. 7.5 Histologic evaluation ofSIS-ECM patches undergoing mechanical stimulation. A) H&E stain and 
E) Movat' s pentachrome stain (collagen stains yellow) for comparison. B) and F) Movat' s pentachrome 
stains of pepsin pretreated SIS-ECM undergoing mechanical stimulation. C) H&E and G) Hematoxylin 
and saffron stains of cell-seeded SIS-ECM undergoing mechanical stimulation. D) H&E and H) 
Hematoxylin and saffron stains of pepsin pretreated and cell-seeded SIS-ECM undergoing mechanical 
stimulation. 
7.6 Immunohistochemistry 
The only IHC stain in the in vitro study that showed any statistical difference 
between groups was the fibronectin stain. More specifically, the cell seeded, pepsin 
digestion group demonstrated less intensity of fibronectin staining compared to the 
samples only digested with pepsin (Fig. 7.6, A-C versus D-F and Fig. 7.7). Staining for 
smooth muscle alpha actin and for PCNA was not statistically different between groups. 
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Fig. 7.6 IHC stain for fibronectin. Antibody stain on top row with controls below. A) CeiJ-seeded only 
SJS-ECM patch undergoing mechanical stimulation B) Pepsin pretreated and cell-seeded SIS-ECM patch 
undergoing mechanical stimulation C) Pepsin pretreated only SIS-ECM patch undergoing mechanical 
stimulation. D) Floating cell-seeded only SIS-ECM patch E) Floating pepsin pretreated and ceiJ-seeded 
SIS-ECM patch. F) Floating pepsin pretreated only SIS-ECM patch. G)-L) Corresponding controls below 
primary antibody stained tissue. 
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Fig. 7. 7 Staining intensity for fibronectin comparing the pepsin digested, ceiJ seeded, and pepsin digested 
and cell seeded groups. Asterisk indicates statistical significance. 
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7. 7 Discussion 
7.1.1 Overall Trends 
In this series of experiments, we used the elastic modulus of the ECM material as 
a surrogate indicator of matrix remodeling. We postulated the following outcomes: 1) 
proteolytic pre-digestion of the ECM material with pepsin would result in a decrease in 
elastic modulus that could not be regained in the absence of living cells; 2) given the 
appropriate growth conditions, seeding the ECM material with cells would provide the 
potential for matrix remodeling, as evidenced by a corresponding increase in elastic 
modulus; 3) the dynamic mechanical environment of the bioreactor would influence the 
VICs' ability to remodel the ECM material. 
With respect to the first outcome, we found that pepsin digestion of the ECM 
resulted in a significant decrease in elastic modulus compared to untreated material, as 
shown in Figure 7 .1. In the cultured samples, in spite of the relatively short time point of 
1 week in culture, SIS-ECM patches exposed to mechanical stimulation showed clear 
differences compared to their floating counterparts. SIS-ECM patches pretreated with 
pepsin and then cultured in the bioreactor became stiffer, yet the groups kept floating for 
7 days had the largest decrease in elastic modulus. Interestingly, the SIS-ECM patches 
that were seeded with MVICs but did not undergo pepsin pretreatment had lower elastic 
modulus following mechanical stimulation than either pepsin pre-treated group, but the 
highest elastic modulus of the floating controls. Mechanical stimulation and enzymatic 
degradation may be symbiotic processes in remodeling of SIS-ECM patches. However, 
none of these observational differences were found to be statistically significant. Further 
studies are needed to confirm the effects of mechanical stimulation and enzymatic 
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degradation. 
Interestingly, pepsin-digested, cell-seeded samples showed a significant and 
noteworthy response to mechanical stress: Under static conditions, pepsin-digested, cell-
seeded ECM samples lost further stiffuess compared to the samples digested with pepsin 
alone, or to those seeded without prior pepsin digestion. However, when similar samples 
were subjected to the mechanical forces encountered in the splashing bioreactor, no such 
loss occurred, suggesting that the lack of mechanical stress either fails to induce a pro-
remodeling response in the seeded VICs, or actively induces an anti-remodeling response 
in these cells. 
Enzymatic degradation likely plays a key role in cell behavior in vitro, as has 
been shown in vivo. MVICs also stained for smooth muscle alpha actin, suggesting cell 
activation. The greatest infiltration ofMVICs into the SIS-ECM patch was seen in those 
patches that were pre-treated with pepsin before seeding with cells. This is echoed in the 
strong fibronectin stain, a marker for cell invasion. In addition, the SIS-ECM patches 
undergoing both pepsin pre-treatment and cell seeding demonstrated greater tissue 
cohesiveness, with less distinct layers visible by microscopy. 
7. 7.2 Limitations 
The present study has several notable limitations. In particular, the number of 
tests that could be run in parallel was limited practically by the size of the bioreactor. 
Small sample size may have confounded statistical interpretation of the data. 
Furthermore, while we used elastic modulus as a surrogate for evidence of matrix 
remodeling, there may be other material characteristics that would give us a more 
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accurate understanding of the matrix dynamics within the ECM material. Finally, 
although our bioreactor has been previously validated, it is a simplified system and does 
not completely encompass all of the many variable encountered in vivo in the mitral 
valve. 
7. 7.3 Future Directions 
While significant changes were seen following one week of dynamic culture, 
longer culture times in the splashing bioreactor would likely continue many of the trends 
observed and allow greater cell integration and proliferation. Strong staining for 
fibronectin was seen in the groups undergoing mechanical stimulation at one week, 
suggesting that MVICs were actively invading the SIS-ECM patch. A longer culture 
duration may give these cells the opportunity to further remodel the SIS-ECM patch by 
proliferating and laying down new ECM. 
Due to their high cost and lesser ease of experimentation, large animal validation 
studies of this SIS-ECM patch material should not be its only method of testing. 
Bioreactor culture has the potential to greatly add to knowledge of the SIS-ECM 
remodeling process and can be used to create good models of matrix degradation and 
invading cell behavior. 
7. 7.4 Conclusions 
Pre-digestion with pepsin, and the presence or absence of mechanical stress, 
appears to play a role in the ability ofVICs to remodel ECM material in a dynamic in 
vitro model of mitral valve repair. SIS-ECM pretreated with pepsin and mechanically 
stimulated demonstrated superior remodeling compared to non-pepsin degraded SIS-
ECM and floating controls. These results will contribute to the goal of creating an in 
vitro model of SIS-ECM remodeling. 
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Chapter 8: Responsibly Managing the Clinical Application of Tissue-Engineered 
Scaffolds: How Ontology May Dictate Ethics 7 
8.1 Introduction 
Although tissue engineering has been described as a field "still in its infancy,"105 
the impact it has already had on patient care and the public consciousness has been 
significant. In the past decade, increasing numbers of tissue engineered-scaffolds have 
become available to repair or replace a myriad of patient tissue. In addition, a paradigm 
shift has occurred; while pluripotent stem cells were once considered the key to tissue 
regeneration, the microenvironment within which cells carry out their function has 
proved equally critical.103•106 Investigators have therefore focused effort on decellularized 
scaffolds that, once implanted, can remodel, bear load, and become populated with 
invading progenitor cells from surrounding tissue?5•45•48 One such promising scaffold, 
SIS-ECM, used in the studies previously detailed, has been used successfully for such 
varied applications as musculotendinous and dura mater replacement, bladder 
reconstruction, body wall, and myocardium repair.7-Io,2o 
The complexity of these scaffolds has led the European Association for 
Bioindustries (EuropaBio) to call for a distinct definition. EuropaBio argues that "it is 
necessary that the definition of human tissue engineered product is differentiated from the 
definition of medicinal product, as well as that for a somatic cell therapy medicinal 
product and gene therapy medicinal product" .107 Defining these tissue-engineered 
products is important, the Association notes, because "existing guidelines are specific for 
7 The majority of this chapter has been submitted to The Lancet and will be published as 
Scully BB, Morales DLS, and Grande-Allen KJ and McCullough LB. Responsibly 
Managing the Clinical Application of Tissue-Engineered Scaffolds: How Ontology May 
Dictate Ethics 
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phannaceutical development and those are not suitable" for tissue-engineered products.107 
Investigators and IRBs are also in need of ethically justified guidelines for responsibly 
managing the clinical innovation of tissue-engineered products. The purposes of this 
paper are to clarify the nature of tissue-engineered scaffolds as undergoing ontologie 
metamorphosis, a concept to be explained, and to identify ethical challenges of this 
metamorphosis. 
8.2 Methods 
EuropaBio is correct: the central issue is ontological. What kind of clinical entity 
are tissue-engineered scaffolds? Clarity about what exactly these scaffolds are, and what 
they are not, is essential for addressing ethical issues. We will use Sulmasy et al.' s 
criteria to distinguish these scaffolds from other available biomaterials, and explore in 
what instances the resulting conceptualization may help to construct the necessary ethical 
framework for approaching these scaffolds.103 We believe that ontology should drive the 
ethical framework that, in turn, should guide clinical application of tissue-engineered 
decellularized scaffolds. 
8.3 Findings 
8.3.1 l>.ntolo~ 
Paola and Walker describe the example of an implantable cardioverter-
defi.brillator (lCD) becoming a part of the patient and introduce the concept ofbiofi.xtures 
to explore whether or not a DNR consent authorizes its inactivation. In doing so, they 
introduce but do not fully develop the concept of an "ontologie metamorphosis", where 
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one thing becomes "a part of something theretofore disjoint."109 Although a tissue-
engineered scaffold can be said to become a part of the patient, it is not like an lCD. We 
submit that a tissue-engineered scaffold goes a step further than an implantable device 
such as an lCD, in that it both becomes part of the patient's physiology, like a device 
would, and additionally stimulates a process of replacement that leads to the original 
scaffold's disappearance and replacement with normal tissue (whereas machines replace 
but remain distinguishable from surrounding anatomy). In this way, the matrix truly does 
undergo an ontological metamorphosis from a separate entity (for example, the 
decellularized matrix that can be derived from porcine small-intestinal submucosa) into 
being replaced by the patient's own cells, with an identical structure and function to the 
surrounding tissue. 
Sulmasy et al. 's criteria for a replacement therapy can be used to demonstrate 
scaffolds' uniqueness. These criteria are (i) the intervention's responsiveness to changes 
in the organism or its environment; (ii) properties such as growth and self-repair; (iii) 
independence from an external energy source or supplies; (iv) independence from 
external control by an expert; (v) immunologic compatibility; and (vi) physical 
integration into the patient's body.108 
8.3.2. The intervention's responsiveness to changes in the organism or its environment 
Decellularized tissue-engineered scaffolds begin to respond to changes in the 
organism immediately upon implantation. Extracellular matrix (ECM), once thought to 
be biologically inert and referred to as the "ground matrix," is now known to be 
constantly adapting in response to its environment and the cells that inhabit it. Matrix 
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metalloproteases break down the existing extracellular matrix and are balanced out by the 
secretion of additional ECM by its inhabiting cells. De Vries et al. note that these 
scaffolds, once populated by the host organisms' cells, contain metabolically active cells 
in a dynamic environment, which mediate an ongoing interaction between the product 
and the recipient's body .105 This dynamism produces variability; as Trommelmans et al 
note, a scaffold "is a dynamic, physiologically active entity and is thus intrinsically 
variable."110 Because each recipient contains her own unique physiology, no two 
implanted scaffolds are alike. 
In the case of decellularized tissue-engineered scaffolds not seeded with cells 
prior to implantation, as opposed to scaffolds containing stem cells or other non-
autologous cells, each recipient provides the cells that populate the scaffold after 
implantation. For scaffolds in contact with blood, such as cardiac patches, cells coming 
from the blood, or circulating progenitor cells, respond to the scaffold environment by 
excreting ECM (as would other cell types) and by changing their phenotype.5 This newly 
excreted matrix eventually replaces the original scaffolding, which continues to be 
broken down. Perhaps more than any implant, tissue-engineered scaffolds respond to 
their environment. 
8.3.3 Properties such as growth and self-repair 
The ability of implanted decellularized scaffolds to grow with the patient and 
repair themselves is considered to be a fundamental characteristic. 5 The entire field of 
tissue engineering, according to de Vries et al, is claimed to be part of a new medical 
paradigm, namely, that of regenerative medicine" .105 EuropaBio argues: "the emphasis 
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for hTEPs should be their tissue regenerative properties" .107 This ability to grow and self-
repair is thought to be one of the great advantages of these scaffolds and has potential to 
transform the treatment of patients with disease processes necessitating tissue 
replacement, particularly those in children and fetuses, where the inability of currently 
available patch materials to grow with the patient has often necessitated frequent 
reoperations until they reach maturity. As seen in Table 1, this ability to grow and self-
repair is one of the distinguishing characteristics of tissue-engineered decellularized 
scaffolds separating them from any implantable biomaterial that has come before. 
Prostheses, synthetic patches, devices, and homograft materials: none of these can grow 
with the patient or repair themselves when damaged. The unprecedented ability of tissue-
engineered scaffolds to grow and repair themselves creates unique ethical challenges, as 
we shall see. 
8.3.4 Independence from external energy sources or supplies 
Once implanted, decellularized scaffolds are completely independent from any 
external energy sources or supplies. This differentiates them from machines, which 
require continuous monitoring and upkeep. Deplazes et al. note that bioengineering 
products ••should functionally be like a machine but [their] origin and development are 
still very close to that of traditional organisms". 111 While they argue that .. the definition 
of an entity as machine seems to allow bypassing the discussion about the assignment and 
evaluation of instrumental and intrinsic values", these values .. can be raised in the case of 
organisms".111 However, their independence from external energy sources or supplies 
does not quite make these scaffolds organisms, either. As seen in Table 1, an 
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independence from external energy sources or supplies is not a new feature of implanted 
biomaterials, as it is shared by technologies as varied as orthopedic hardware, prostheses, 
patch materials, cadaveric tissue, and human tissue and organ transplants (Table 1 ). 
8.3.5 Independence from external control by an expert 
Once implanted these scaffolds function independently of any external control. 
Although implanted tissue engineered scaffolds may potentially be monitored by an 
expert, for instance with serial MRis, such an expert could exert minimal if any control 
over the scaffold. Unlike a transplanted organ, whose effect on the surrounding tissue is 
modulated by an expert-controlled regimen of medication according to imaging and other 
studies, or an implanted device that can be manipulated, these scaffolds operate 
completely independently of the experts who implant them. Sulmasy et al. note: "the 
most important feature of a replacement therapy is that it provides the function that has 
been pathologically lost."108 Although a substitute therapy, such as peritoneal dialysis, 
requires external control by an expert or team of experts, a replacement therapy does not. 
Their independence from external control by an expert makes these scaffolds 
similar to cadaveric and human tissue transplants, which share this characteristic with 
orthopedic hardware and prostheses and patch material. In contrast, implanted drug 
delivery systems, devices, and human organ transplants require extensive outside control. 
While Sulmasy et al. argue that a transplanted organ constitutes a replacement therapy by 
this definition, here we can see a further distinction for decellularized scaffolds: unlike a 
transplanted organ, which does in fact require the control of a specialized team of experts, 
and whose effects on a patient's body can be modified, for instance by 
immunosuppressants, once implanted a scaffold is truly independent of outside expert 
control, suggesting that these scaffolds are more of a replacement than transplanted 
organs. Because of this distinction, we propose the phrase "autonomous replacement 
therapy," which emphasizes tissue-engineered scaffolds' unique independence from 
external control by an expert. 
8.3. 6 Immunologic compatibility 
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Like the ability to grow and self-repair, the immunogenicity of decellularized 
scaffolds is key to their identification as such. By removing cells, it is believed that most 
antigenic elements are eliminated, avoiding an immunological response in the recipient. 
In addition, collagen is the primary matrix element in these scaffolds, and is considered 
minimally antigenic. 5 This limited immunogenicity removes the need for tissue typing, 
which plagues organ transplantation, or the addition of a synthetic or drug-releasing 
barrier, such as that found in implanted devices like coronary artery stents. Because the 
high immunologic compatibility of these scaffolds contributes to their independence from 
any outside control (in the form of physicians prescribing immunosuppressants, for 
instance), it is a critical characteristic making them autonomous replacement therapies. 
8.3. 7 Physical integration into the patient's body 
This integration again separates these scaffolds from the majority of other 
implantable biomaterials, suggesting that the way we view them should differ as well. 
Because of their immediate remodeling upon implantation, decellularized scaffolds are 
rapidly integrated into the patient's body. De Vries et al. therefore note that implanting a 
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tissue-engineered product is an "irreversible process," one that additionally suggests that 
these are replacement therapies. Researchers have combined decellularized scaffolds with 
autologous cells, for instance in the development of tissue-engineered valve stents, a 
technology that is theoretically reversible.112 However, it is the astonishing potential 
extent of their integration that has made these scaffolds a source of great hope for 
clinicians. This integration also makes them more of a replacement therapy than other 
patch materials, which can ultimately be rejected by the body and become calcified or 
thrombotic?·3 
Unlike all other implantable biomaterials including organ transplantation, these 
scaffolds meet every one of Sulmasy' s criteria for replacement therapies. As such, we 
must view them as novel entities in that they uniquely undergo a complete ontologie 
metamorphosis into autonomous replacement therapies. Any adequate ethical framework 
must take account of this novelty. 
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Table 8.1 Characteristics of Implantable Biomaterials 
Implanted Examples Responds to Can Independence Independence Immunologic Physical lrrevers Off-
biomaterial change in grow from external from external compatibility Integration -ible the-
organism or and energy control by an into the process shelf 
environment self- sources or expert patient's avail a-
repair supplies body bility 
Orthopedic Stabilizing pin, + + + + 
hardware plate 
Prostheses Hip, knee + + + + 
replacement, 
PMMAfor 
chest wall 
Synthetic + + + + 
meshes 
Synthetic Dacron, + + + + + 
patch Gortex 
Drug-eluting Stents + + 
implants 
Implantable Insulin pumps, 
drug delivery birth control + 
Short-term VADs + + 
devices 
Destination VADs, ICDs, 
devices pacemakers + + + 
Cadeveric Heart valves, 
tissue corneas + + + + + 
Humantisue Blood, bone 
transplants marrow, veins + + for coronary + +I- + + 
artery bypass 
Human organ Heart, lungs, 
transplants kidney, liver + + + 
Human cell- Bone 
seeded scaffolds, + + + + +* + + 
scaffolds skin grafts 
Decellularized SIS-ECM, 
extracellular UBM 
matrix (urinary + + + + + + + + bladder 
scaffolds matrix), 
dttellularized 
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8.4 Ethical Challenges 
In order to distinguish these scaffolds from other implantable biomaterials, we 
have created a table that maps out their characteristics (Table 8.1). As is shown here, 
decellularized scaffolds differ from destination devices such as ICDs in five 
characteristics, four of which together represent two-thirds of Sulmasy' s criteria: unlike 
ICDs, decllularized scaffolds can grow and self-repair, are independent from external 
energy sources or supplies and control by an expert, and are immunologically compatible 
with the host organism. In addition to these characteristics, the implantation of these 
scaffolds is a largely irreversible process. Just as it is impossible to remove blood infused 
into a patient from a donor, because it becomes so integrated with the patient's existing 
blood, once a tissue-engineered scaffold is implanted its integration into the existing 
tissue is so extensive that it becomes impossible to distinguish the implanted tissue from 
the native. The extent of implanted decellularized tissue-engineered patches' response to 
changes between organisms and environments suggests that they are a true replacement 
therapy. 
Tissue engineering scaffolds are unique, because as we have seen with their 
unique fulfillment ofSulmasy's criteria, they undergo a complete ontologie 
metamorphosis from implantable patch to functioning part of the patient's anatomy. In 
the case of decellularized tissue-engineered scaffolds, as seen in Table 8.1, they are also 
unique in being available "off the shelf," making them available for immediate use in 
patients. As the ontological investigation of tissue-engineered scaffolds has shown, the 
main advantages of these technologies constitute their greatest ethical challenges. 
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First, the unprecedented ability of these scaffolds to grow and self-repair may prove 
clinically risky. Trommelmans et al note: '"against an enormous benefit stand potential 
large risks, probably even emergent risks due to the process of regeneration that have 
never before been encountered."110 As a true replacement therapy, scaffolds will be 
irreversible and clinical risks, especially long-term ones, may be unavoidable. Because of 
this, there has been a growing interest in how to manage emerging biotechnologies' risks 
without limiting their potential benefits. Gutmann et al. recently identified the ideals of 
public beneficence, which requires vigilance ""about risks and harms, standing ready to 
revise policies that pursue potential benefits with insufficient caution," and intellectual 
freedom, which argues "'when new technologies intended for good may be used to cause 
harm-these risks alone are generally insufficient to justifY limits on intellectual 
freedom." 113 The risks posed by matrix scaffolds have not been proven to outweigh their 
potential benefits, making their continued use ethically justifiable. 
Here we must also be cognizant of the biasing potential of investigator 
enthusiasm, defined as the detachment of clinical judgment from the discipline of 
evidence-based reasoning. The promise of these scaffolds is certainly tantalizing, but the 
need for an optimal biomaterial for patient applications may obscure their flaws, and lead 
to premature implementation in human subjects, particularly in children, and even 
fetuses, whose current lack of implantable tissues that can grow with them often 
necessitates multiple reoperations that contribute to increased morbidity. Investigators 
have already begun to explore extracellular matrices' potential for intrauterine repair of 
congenital disorders, such as spina bifida.115 Investigation needs to identifY short-term 
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and long-term risks, so that patients can be as well-informed as possible, presuming long-
term risks do not outweigh benefits. 
Second, unlike other implantable biomaterials, and even distinct from 
transplanted human tissues such as blood or bone marrow, these scaffolds are minimally 
immunogenic; however, the risk of an immune response is greater due to the extent of 
their integration into the host organism. In addition, this greater immunologic 
compatibility may make the removal of these scaffolds less permissible than other 
implantable biomaterials. Whereas an implanted organ, when it evokes an overtly strong 
immune response, may be taken out and replaced, these scaffolds behave more like 
human tissue transplants, such as blood and bone marrow, which can be typed to avoid 
immunologic cross-reactivity but can be especially dangerous when they do induce an 
immune response (such as in transfusion reactions in the case of an incorrect blood type 
or graft versus host disease following bone marrow transplantation). The increased risk 
posed by their extensive integration requires the informed consent process for these 
scaffolds to be more rigorous if being used for the purpose of tissue remodeling. 
Perhaps the greatest challenge of all will be the problem of enthusiasm, which may 
undermine such rigorous investigation, considering the great need that exists for such 
patch materials. Like cloning, which has been called the "holy grail of medicine"116 for 
its potential regenerative properties, there will be risks to the technology of tissue-
engineered scaffolds, some of which may not be discovered for years. In addition, for 
many of these scaffolds, FDA approval may only require proofthat they are "as good as" 
other available patch materials, negating the need for a more costly investigation of all of 
the scaffolds' properties and mechanisms. Such patches should only be used for the 
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existing FDA indications. If a material is being used for a FDA approved function such 
as replacement of bladder wall or d~ then consent can be similar as when a nonspecific 
patch material is used. However, if it is being used for remodeling purposes and is not 
FDA approved for this purpose, then patients should specifically consent to the use of a 
matrix scaffold. Physicians should ensure they understand these scaffolds' unique 
benefits and risk, in order for them to make a truly informed decision. 
The FDA cannot, however, regulate what is said to patients and their families. 
Without an FDA approved indication for tissue remodeling, a clinician should in no way 
say or indicate to a patient or their family that a patch is being used for this indication 
unless they are performing a study and have an IRB approved consent form. Physicians 
must be careful to use clinically accurate, non-exaggerating language when describing 
these technologies to patients and keep in mind that these potential risks must be 
considered in the context of the overall benefits. However, if physicians use these new 
technologies for their FDA approved indications, they on firm ethical ground. 
8.5 Conclusions 
As tissue-engineered scaffolds are used in more and more tissues and gain 
acceptance for a host of new applications, the ethical framework with which physicians 
use them will be influenced by how they are defined. As we have seen, these scaffolds 
fulfill all of Sulmasy' s criteria for replacement therapies, making them distinct from other 
available implantable biomaterials. Tissue-engineered scaffolds are unique in their 
complete ontologie metamorphosis and pose distinctive ethical challenges that must be 
responsibly managed. In particular, enthusiasm in the media and lay public, fed by the 
medical community, must be carefully controlled. Clinical use should be only for FDA 
approved indications unless an IRB-approved study is underway. Physicians, IRBs and 
other regulatory bodies will need to take these distinctions into account when 
constructing ethical frameworks with which to view this technology. However, this 
responsibility should not detract from the exciting potential that tissue-engineered 
scaffolds may have in treating and potentially curing many human illnesses. 
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Chapter 9: Implications and Future Directions 
9.1 Implications 
9.1.1 Clinical Significance 
A cardiovascular patch with the ability to remodel and grow with the patient 
would transform the care of children and adults with congenital heart diseases such as 
tetralogy ofF allot, as well as be applicable to countless other cardiovascular applications. 
This body of work evaluated the potential of the juvenile ovine model for investigations 
of the remodeling of a newly available SIS-ECM patch via a large variety of 
experimental modalities. The novelty of this work lies in the use of a larger SIS-ECM 
patch than has been previously described for repair ofvessels,96 its placement in the 
RVOT, and in the use of a novel bioreactor to further investigate its remodeling processes. 
This work is the basis for a larger study soon to be underway, and has attempted to apply 
an exhaustive panel of characterizations towards assessing the remodeling potential of an 
extremely promising tissue-engineered cardiac patch. 
9.1.2 Ethical Considerations 
As tissue-engineered scaffolds are used in more and more tissues and gain 
acceptance for a host of new applications, the ethical framework with which physicians 
use them will be influenced by how they are defined. Tissue-engineered scaffolds are 
unique in their complete ontologie metamorphosis (going from scaffold material to a part 
of the patient's own tissue) and pose distinctive ethical challenges that must be 
responsibly managed. In particular, enthusiasm in the media and lay public, fed by the 
medical community, must be carefully controlled. Contract studies, such as the research 
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presented in chapters 3-5, that are funded by the medical device industry require close 
scrutiny and extra precautions to avoid conflicts of interest. Clinical use should be only 
for FDA approved indications unless an IRB-approved study is underway. Physicians, 
IRBs and other regulatory bodies will need to take these distinctions into account when 
constructing ethical frameworks with which to view this technology. However, this 
responsibility should not detract from the exciting potential that tissue-engineered 
scaffolds may have in treating and potentially curing many human illnesses. 
9.2 Future Directions 
A significant limitation of the in vivo study is the very small sample size, 
confounded by the fact that only 2 of the 4 hearts were successfully reperfused for the 
optical mapping experiment. There was also no comparator patch material used to serve 
as a negative control or to provide a comparison with the closest alternative patch. 
Nevertheless, these preliminary results showing functional electrical activity within the 
implanted patch are remarkable and, to our knowledge, unprecedented for any patch 
material currently used for human cardiac repair. In the future, we plan to extend this line 
of investigation using a larger number of animals, and including a comparator arm, most 
likely using bovine pericardium as control material. In addition to the experiments 
already performed, we intend to perform gadolinium-enhanced magnetic resonance 
imaging to assess wall motion and muscle-tissue viability and motility using a 3T whole-
body MR system using a phased-array receiver coil and vector electrocardiogram for R-
wave triggering. In addition, 3-D electrical mapping using a 3-D electrophysiological 
mapping system will be used to create an anatomic voltage map and a 3D 
activation/propagation map of the RV. Sonomicrometry will also be used to compare 
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contractility in the patch materials versus myocardial tissue, and additional histology and 
mechanical testing will be used to confirm and extend the results of this study. 
A significant addition to this work would be a continued in vitro investigation 
using the splashing bioreactor described in chapters 6-7, with longer time points and 
perhaps using other enzymes, such as papain, to degrade the matrix. In addition, more 
precise strain mapping analysis would contribute to a greater knowledge of the material 
properties of the remodeling tissue. 
Human validation of the patch material would be an important next step in 
serving our pediatric population. One patient population in particular that would be a 
potential candidate for such research would be patients with tetralogy ofFallot who 
undergo reoperation for pulmonary valve replacement requiring reconstruction of their 
right ventricular outflow tracts necessitating new patch material. To determine whether 
the patch has remodeled we could follow up with a variety of imaging techniques, 
including magnetic resonance imaging (MRI) with gadollinium for viability imaging, 
echocardiography to measure tissue strain, and positron emission tomography (PET) scan 
with glucose uptake for metabolic imaging. 
9.3 Conclusions 
In conclusion, we have found that an SIS-ECM patch, when surgically implanted 
in the ovine RVOT, aorta and PA, is capable of constructive remodeling as evidenced by 
electrical, histological and mechanical properties. The juvenile ovine model appears 
suitable for assessing this novel patch's remodeling potential, allowing evaluation of cell 
infiltration, cell phenotype, and remodeling extracellular matrix properties, including 
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change in elastic modulus, collagen composition and calcification. Additionally, in the 
RVOT the juvenile ovine model proves suitable for assessing conduction of an electrical 
signaL In addition, a splashing bioreactor has proved to be an excellent culture 
environment for the investigation of the SIS-ECM patch's remodeling. Based on the 
limitations with this study, the promise of remodeling associated with SIS merits further 
investigation in further studies. As tissue-engineered scaffolds are used in more and more 
tissues and gain acceptance for a host of new applications, the ethical framework with 
which physicians use them will be influenced by how they are defined. However, while 
further studies are needed for validation of this patch, these series of studies have shed 
important light on the remodeling ability of a novel cardiovascular patch, which has the 
potential to transform the care of a needy patient population. 
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APPENDIX I 
1. heart.m 
The following program allows you to apply ax and y- dim mean filter over the 
data. The inputs into the program are the start and end times, the range of x and y pixels 
and the mean filter across a certain x and y dimension. The output is the graph of the data 
in plot format for each averaged pixel. The output is saved as an image and evaluated. 
function heart(prefix,directory,stime,etime,xps,yps,xpe,ype,x,y,dig) 
ndirectory = directory; 
tl = stime:etime; 
disp(ndirectory}; 
xval = xpe-xps+l; 
yval = ype-yps+l; 
col= (mod(xval,x)-(xval}}/-x; 
row= (mod(yval,y}-(yval}}/-y; 
intense =zeros(stime-etime+l,row*col}; 
t = '. tif'; 
digit= '0'; 
for i = l:dig-2 
digit= strcat('O',digit}; 
end 
counter = 1; 
for i = l:etime-stime+l 
vall= lOA(counter-1); 
val2 = lOAcounter; 
end 
if i>=vall && i<val2 
else 
end 
n = strcat(digit,num2str(i}}; 
counter = counter+l; 
digit= digit(l:dig-(counter}}; 
n = strcat(digit,num2str(i)); 
file strcat(ndirectory, '\',prefix, '-',n,t}; 
I= imread(file}; 
Inew = I(yps:ype,xps:xpe}; 
imshow (I new} 
for j = l:y:ype-yps+l 
for k = l:x:xpe-xps+l 
end 
aver= mean(mean(Inew(j:j+(y-l},k:k+(x-1}}}}; 
act= col*(j-l}+(k}; 
intense(i,act}= aver; 
end 
if(floor(i/lOOO}==i/1000) 
disp(i} 
end 
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figure('OuterPosition', [0,0,1333,1000], 'Name',strcat(directory, '-
',prefix)) 
subplot 
for i =1:row*col 
subplot(row,col,i) 
plot(t1,intense(:,i)) 
end 
saveas(gcf,strcat(directory, '-',prefix, '.tif')) 
end 
2. slopecalc.m 
The following code checks the data for the slope, to see regions where action potentials 
could begin. 
y size(data,1); 
x = size(data,2); 
t size(data,3); 
for i =1:y 
for j = l:x 
for k = 1:t-6 
p = polyfit([1:6],data(k:k+5),1); 
slope(i,j,k)= p(l); 
end 
end 
end 
3. runall.m 
The following program allows you to input a certain folder and calculates the phase shift, 
absolute, frequencies, and time shift values of the images within the files. You can edit 
the start and end values within the code. A Gaussian convolution kernel is added to help 
filter the image data. Absv returns the absolute value of the fourier transform of the data. 
Freqv is the maximum frequency for the fourier transform for that pixel. This helps 
identifY the most significant signals in the data. Phav returns the phase values to show 
where in the phase the signals are and timesv is calculated from the phase. All values are 
saved in values.mat 
function [phav,absv,freqv,timesv] runall () 
listing= dir('*.tif'); 
pies= size(listing); 
[m n] = size(imread(listing(1) .name)); 
data= zeros(m,n,pics); 
for i = 1:pics 
data(:,:,i) = imread(listing(i) .name}; 
end 
ti 1; 
tf pies; 
xs 1; 
xe n; 
ys 1; 
ye m; 
disp('gaussian convolution kernel') 
t1 = ti:tf; 
data= double(data); 
[x y t]= size(data); 
for i 1:t 
end 
I = data (:, :, i) ; 
H = fspecial('gaussian',[3 3],0.631); 
filtdata(:,:,i) = imfilter(I,H, 'replicate'}; 
if(floor(i/1000}*1000==i) 
disp(i) 
end 
disp ('fourier') 
cropdata = data(ys:ye,xs:xe,ti:tf); 
for x = 1:xe-xs+1 
end 
for y = 1:ye-ys+1 
end 
val= fft(double(squeeze(cropdata(y,x,:)})); 
absv(y,x,:) = abs(val); 
[maxva1,loc]=max(absv(y,x,:)); 
freqv(y,x) = loc; 
phav(y,x) = phase(val(loc)); 
timesv(y,x) = phav(y,x)/(2*pi)*freqv(y,x}; 
save ('values'); 
clear all 
end 
111 
112 
APPENDIX2 
The following MA TLAB code was used to analyze the displacement of charcoal 
dots applied to the tissue and generate maps that illustrate regional tissue strain 
(descriptions only, digital file due to length). 
1. Filelist_generator.m 
function [FileNameBase,PathNameBase,filenamelist]=filelist_generator 
% Code to construct a list of 9999 or less filenames 
% Programmed by Rob, changed by Chris. Automatic filelist generation 
% and image time aquisition added by Chris. 
% Last revision: 12/25/06 
2. Grid_generator.m 
function [grid_x,grid_y]=grid_generator(FileNameBase,PathNameBase); 
% Code to generate the DIC analysis grid 
% Completely rewritten by Chris 
% Programmed first by Dan and Rob 
% 
% Last revision: 12/27/06 
% The grid_generator function will help you create grids of markers. 
The 
% dialog has different options allowing you to create a marker grid 
which is rectangular, 
% circular, a line or two rectangels of a shape or contains only of two 
% markers. After choosing one of the shapes you will be asked for the 
base 
% image which is typically your first image. After opening that image 
you 
% will be asked to click at the sites of interest and the markers will 
be 
% plotted on top of your image. You can choose if you want to keep 
these 
% markers or if you want to try again. 
% It has to be noted that you can 
% always generate your own marker positions. Therefore the marker 
position 
% in pixel has to be saved as a text based format where the x-position 
is 
% saved as grid_x.dat and the y-position saved as grid_y.dat. 
% 
2. Displacement.m 
% Initialize data 
% written by Chris and Dan 
% Displacement.m allows you to analyze the data you aquiered with the 
% correlation, fitting or mean routine. It only needs the validx and 
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% validy and can calculate strain from it. Before you start you should 
% consider cleaning up the data as described in the guide. After that 
step 
% you can analyze parts of your data, or the full set. Try to use also 
the 
% console command, e.g. if you want to analyze only image 100-110 since 
% something really interesting happend there, load validx and validy 
into 
% your workspace and call 
% displacement(validx(:,100:110),validy(:,100:110)); 
% In this case displacement only loads the important images and you can 
% clean this part of your data set. 
function 
[validx,validy,displx,disply]=delete_jumpers(validx,validy,displx,displ 
y); 
% written by Chris Durst 
% This is a filter which helps to find jumpy data points which are 
% oscillating or stop moving. 
% The Filter starts by finding the next 10 datapoint neighbours 
% (num_neighbours), calculates their mean position and then plots the 
% difference between each data point and its neighbours versus image 
% number. If a data point is jumping around it will show up as a spike. 
But 
% be careful, one bad one will also affect his neighbours, therefore 
its 
% worthwhile to use this filter step by step. 
APPENDIX3 
1. Macro to quantify DAB intensity 
II Find threshold value 
macro "control [l]" { 
open(); 
dir = getDirectory("image"); 
name = getTitle; 
mainimage=name; 
choices = newArray("Native", "Patch", "Transition"); 
Dialog.create("Select choice"); 
Dialog.addKessage("Select area of anaylsis. "); 
Dialog.addChoice("-->", choices); 
Dialog. show ( ) ; 
choice2 = Dialog.getChoice(); 
Dialog.create("Number of ROI?"); 
Dialog.addKessage("Enter the number of selections to be analyzed"); 
Dialog.addNumber("# of selections", 0); 
Dialog. show ( ) ; 
m = Dialog.getNumber(); 
I /run( "Duplicate ••• ", "title=ROI"); 
for (i=O; i<m; i++) { 
title= "ROI"; 
} 
msg = "After selecting ROI with the brush tool, click \"OK\"."; 
waitForuser(title, msg); 
roiManager ( "add" ) ; 
roiManager("Show All"); 
roiManager("OR"); 
run("Clear Outside"); 
roiManager("Delete"); 
roiManager("Deselect"); 
title = "Preview"; 
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msg = "After previewing image for areas to be removed, click \"OK\"."; 
waitForUser(title, msg); 
choices= newArray("Yes", "No"); 
var choice=""; 
Dialog.create("Select choice"); 
Dialog.addKessage("Are there any areas that need to be removed?"); 
Dialog.addChoice("-->", choices); 
Dialog. show( ) ; 
choice= Dialog.getChoice(); 
if (choice== "Yes") { 
title= "Removal"; 
msg = "After selecting area to be removed with the brush tool, 
click \"OK\"."; 
waitForuser(title, msg); 
roiManager("add"); 
roiManager("Show All"); 
breakcheck = 1; 
while(breakcheck == 1) { 
Dialog.create("Select choice"); 
removed?"); 
Dialog.addMessage("Are there any areas that need to be 
Dialog.addChoice("-->", choices); 
Dialog. show ( ) ; 
choice= Dialog.getChoice(); 
if (choice== "Yes") { 
title= "Removal"; 
msg = "After selecting area to be removed with the 
brush tool, click \"OK\"."; 
} 
else { 
} 
} 
} 
waitForuser(title, msg); 
roiManager ( "add" ) ; 
breakcheck = 0; 
roiManager("OR"); 
run( "Clear"); 
roiManager("Delete"); 
if (choice2 == "Native") { 
pathoutlines=dir+name + "-native-roi"; 
saveAs("tiff", pathoutlines); 
} 
else if (choice2 == "Patch") { 
pathoutlines=dir+name + "-patch-roi"; 
saveAs("tiff", pathoutlines); 
} 
run("Subtract Background ••• ", "rolling=150 light sliding"); 
run("Colour Deconvolution", "vectors=[H DAB]"); 
close(); 
//run("B-bit"); 
run ( "Threshold ••• " ) ; 
title= "Threshold"; 
msg = "Use the \"Threshold\" tool to\nadjust the threshold, after 
recording value, click \"OK\"."; 
waitForUser(title, msg); 
close(); 
close(); 
close(); 
close(); 
} 
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} 
II Perform Analysis 
macro "dabquant [2)" { 
open(); 
dir = getDirectory("image"); 
name = getTitle; 
mainimage=name; 
choices = newArray( "Native", "Patch", "Transition"); 
Dialog.create("Select choice"); 
Dialog.addHessage("Select area of anaylsis. "); 
Dialog.addChoice("-->", choices); 
Dialog. show(); 
choice2 = Dialog.getChoice(); 
Dialog.create( "Number of ROI?"); 
Dialog.addHessage("Enter the number of selections to be analyzed"); 
Dialog.addNumber("# of selections", 0); 
Dialog. show( ) ; 
m = Dialog.getNumber(); 
run("Duplicate ••• ", "title=ROI"); 
for (i=O; i<m; i++) { 
title= "ROI"; 
} 
msg = "After selecting ROI with the brush tool, click \"OK\"."; 
waitForUser(title, msg); 
roiManager ( "add" ) ; 
roiManager("Show All"); 
roiManager( "OR"); 
run("Clear Outside"); 
roiManager("Delete"); 
choices = newArray( "Yes", "No"); 
var choice=""; 
Dialog.create("Select choice"); 
Dialog.addHessage("Are there any areas that need to be removed?"); 
Dialog.addChoice("-->", choices); 
Dialog. show( ) ; 
choice= Dialog.getChoice(); 
if (choice== "Yes") { 
title= "Removal"; 
msg = "After selecting area to be removed with the brush tool, 
click \"OK\"."; 
waitForUser(title, msg); 
roiManager ( "add" ) ; 
roiManager("Show All"); 
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breakcheck = 1; 
while(breakcheck == 1) { 
Dialog.create("Select choice"); 
Dialog.addMessage("Are there any areas that need to be 
removed?"); 
Dialog.addChoice("-->", choices); 
Dialog. show(); 
choice= Dialog.getChoice(); 
if (choice== "Yes") { 
title= "Removal"; 
msg = "After selecting area to be removed with the 
brush tool, click \"OK\"."; 
} 
else { 
} 
} 
} 
waitForuser(title, msg); 
roiManager ( "add" ) ; 
breakcheck = 0; 
roiManager( "OR"); 
run( "Clear"); 
//roiManager("Delete"); 
if (choice2 == "Native") { 
pathoutlines=dir+name + "-native-roi"; 
saveAs("tiff", pathoutlines); 
} 
else if (choice2 == "Patch") { 
pathoutlines=dir+name + "-patch-roi"; 
saveAs("tiff", pathoutlines); 
} 
else if (choice2 == "Transition") { 
pathoutlines=dir+name + "-transition-roi"; 
saveAs("tiff", pathoutlines); 
} 
run("Subtract Background ••• ", "rolling=150 light sliding"); 
run("Colour Deconvolution", "vectors=[H DAB]"); 
close(); 
rename ( "dab image" ) ; 
run("Duplicate ••• ", "title=DAB"); 
//run("8-bit"); 
run("Threshold ••• "); 
Dialog.create("Threshold values"); 
Dialog.addMessage("Enter the lower and upper threshold limits"); 
Dialog.addNumber("Lower_Threshold", 0); 
Dialog.addNumber("Upper_Threshold", 255); 
Dialog. show ( ) ; 
Lower_Threshold = Dialog.getNumber(); 
Upper_Threshold = Dialog.getNumber(); 
setThreshold(Lower_Threshold, Upper_Threshold); 
run( "Convert to Mask"); 
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run("Fill Holes"); 
run("Set Measurements ••• ", "area mean min display redirect=dabimage 
decimal=3" ) ; 
run("Analyze Particles ••• ", "size=40.0-Infinity circularity=0.00-1.00 
show=Outlines display include"); 
outlines=getTitle; 
selectWindow(outlines); 
run( "Copy"); 
close(); 
if (choice2 == "Native") { 
} 
measurename =name+ "-native.xls"; 
measurepath=dir+measurename; 
saveAs("Measurements", measurepath); 
run( "Close"); 
close(); 
selectwindow(mainimage); 
setPasteMode("AND"); 
run( "Paste"); 
pathoutlines=dir+name + "-native-outlines"; 
saveAs("tiff", pathoutlines); 
else if (choice2 == "Patch") { 
measurename =name+ "-patch.xls"; 
measurepath=dir+measurename; 
saveAs("Measurements", measurepath); 
run( "Close"); 
} 
close(); 
selectWindow(mainimage); 
setPasteMode("AND"); 
run( "Paste"); 
pathoutlines=dir+name + "-patch-outlines"; 
saveAs("tiff", pathoutlines); 
roiManager("delete"); 
close(); 
close(); 
close(); 
close(); 
close(); 
} 
} 
II Find Area 
macro "area [3]" { 
open(); 
dir = getDirectory("image"); 
name = getTitle; 
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mainimage=name; 
run("Subtract Background ••• ", "rolling=150 light sliding"); 
run("Colour Deconvolution", "vectors=[H DAB)"); 
close(); 
rename ( "area" ) ; 
run("Convert to Mask"); 
run("Set Measurements ••• ", "area mean min display redirect=area 
decimal=3"); 
run("Analyze Particles ••• ", "size=40.0-Infinity circularity=0.00-1.00 
show=Outlines display"); 
index= lastindexOf(name, "."); 
if (index!=-1) { 
name= substring(name, 0, index); 
measurename =name+ "-a.xls"; 
measurepath=dir+measurename; 
saveAs ("Measurements", measurepath) ; 
pathoutlines=dir+name + "-a-outlines"; 
saveAs("tiff", pathoutlines); 
run("Clear Results"); 
close(); 
close(); 
close(); 
close(); 
close(); 
close(); 
} 
} 
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